_		Under the Laperwo	IN I IBUU	AUTHA OF 1880, NO persons as	s required to respond to a corection or	From allor or ress it contains a valid CIVIB control number		
	Substitute	for form 1449A/PTC)		Complete if Known			
					Application Number	10/788,426		
INFORMATION DISCLOSURE					Filing Date	March 1, 2004		
	STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas		
					Art Unit	1625		
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
V	Sheet	1	of	37	Attorney Docket Number	BAYER-0044		

Examiner initiass	Document Number Number - Kind Code' (if known) 502,504 1,792,155 2,043,375 2,032,265 2,289,422 2,849,476 2,683,082	Publication Date MM-DD-YYYY 08-01-1893 02-10-1931 07-07-1936 09-14-1937 06-30-1942	Thoms Fitzky Goldstein et al.	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A22 A24 A24 A25 A26 A27 A28 A29 A30 A31	1,792,156 2,046,375 2,093,265 2,288,422 2,649,476 2,683,082	02-10-1931 07-07-1936 09-14-1937	Fitzky Goldstein et al.	
A3 A4 A5 A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A22 A24 A25 A26 A27 A28 A29 A20 A21 A24 A25 A26 A27 A28 A29 A29 A20 A21 A21 A22 A22 A23 A24 A25 A25 A26 A27 A28 A29	2,046,375 2,093,265 2,288,422 2,649,476 2,683,082	07-07-1936 09-14-1937	Goldstein et al.	
A4 A5 A5 A6	2,093,265 2,288,422 2,649,476 2,683,082	09-14-1937		1
A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 A16 A17 A16 A17 A18 A20	2,288,422 2,649,476 2,683,082			
A6 A7 A8 A9 A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A24 A24 A25 A26 A27 A28 A30 A31 A31 A31 A31 A31 A32	2,649,476 2,683,082	06-30-1942	Coffey et al.	
A7 A8 A9 A10 A10 A11 A11 A12 A13 A14 A15 A16 A17 A18 A20 A20 A22 A22 A22 A24 A27 A28 A20 A20 A20 A20 A21 A22 A22 A23 A24 A24 A27 A28 A29 A20 A20 A20 A21 A20 A21 A22 A22 A23 A24 A24 A27 A28 A29 A20	2,683,082		Rohm	
A8 A9 A9 A10 A11 A12 A13 A14 A15 A16 A17 A19 A20 A21 A22 A23 A24 A26 A27 A28 A28 A29 A29 A29 A29 A29 A30 A31	-,,	08-18-1953	Martin	
A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A22 A24 A27 A28 A26 A27 A28 A29 A20 A30 A31		07-06-1954	Hill et al.	
A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A26 A27 A28 A29 A20 A21 A28 A29 A20 A21 A21 A22 A23 A24 A25 A26 A27 A27 A28 A28 A29 A29 A30 A31	2,722,544	11-01-1955	Martin	
A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A22 A22 A24 A25 A26 A27 A28 A27 A28 A29 A30 A31	2,745,874	05-15-1956	Schetty et al.	
A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A28 A29 A30 A31	2,781,330	02-12-1957	Downey	
A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A22 A22 A23 A24 A25 A26 A27 A30 A31 A31 A32	2,797,214	06-25-1957	Bossard	
A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A27 A28 A29 A30 A31	2,867,659	01-06-1959	Model et al.	
A15 A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A26 A27 A28 A29 A30 A31 A31	2,877,268	03-10-1959	Applegath et al.	
A16 A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A27 A28 A29 A30 A31	2,960,488	11-15-1960	Tamblyn et al.	
A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31 A31	2,973,386	02-28-1961	Weldon	
A18 A19 A20 A21 A22 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31	3,151,023	09-29-1964	Martin	
A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A27 A28 A29 A30 A31 A32	3,200,035	08-10-1965	Martin et al.	
A20 A21 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31	3.230.141	01-18-1966	Frick et al.	
A21 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31	3,284,433	11-08-1966	Becker et al.	
A22 A23 A24 A25 A26 A27 A28 A29 A30 A31	3,424,760	01-28-1969	Helsley et al.	
A23 A24 A25 A26 A27 A28 A29 A30 A31	3,424,761	01-28-1969	Helsley et al.	
A24 A25 A26 A27 A28 A29 A30 A31	3,424,762	01-28-1969	Helsley	
A25 A26 A27 A28 A29 A30 A31	3,547,940	12-15-1970	Brantley	
A26 A27 A28 A29 A30 A31	3,639,668	02-01-1972	Alles et al.	
A27 A28 A29 A30 A31 A32	3,646,059	02-29-1972	Brantley	
A28 A29 A30 A31 A32	3,668,222	06-06-1972	Hauser	
A29 A30 A31 A32	3,689,550	09-05-1972	Schellenbaum et al	
A30 A31 A32	3,743,498	07-03-1973	Brantley	
A31 A32	3,754,887	08-28-1973	Brantley	
A32	3,823,161	07-09-1974	Lesser	
A32	3,828,001	08-06-1974	Broad et al.	1
	3.860.645	01-14-1975	Nikawitz	
	3,990,879	11-09-1976	Soper	1
A34	4.001.256	01-04-1977	Caliahan et al.	
A35	4.009.847	03-01-1977	Aldrich et al	
A36	4.042.372	08-16-1977	Harper	†
A37	4.062.861	12-13-1977	Yukinaga et al.	
A37a	4.063.928	12-20-1977	Johnston	1

Signature Considered UTTI-JCUTT

FEXANINER Initial is reference considered, whether or not datation is in conformance with MFFF 800 D was line through clasted in fine or conformance and not considered include cycy of this form with near communication to applicant. 'Applicant's unapse clastics designation number (coptional). 'See Refind Codes of USFT P Parent Documents and was applicant.' Applicant's unapse clastics designation number (coptional). 'See Refind Codes of USFT P Parent Documents and Codes of USFT P Parent P Parent Documents and Codes of USFT P Parent P Parent P Parent P Parent P Parent P Parent P P P Parent P P P P P P P P P P P

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

1	Substitute	for form	449A/PTC)					Compl	ete if Known
							Applic.	ation Number	10/78	88,426
	INFO	RMA	TION	DIS	CLOSU	IRE	Filing I	Date	Marc	h 1, 2004
	STAT	TEME	NT B	Y A	PPLICA	NT	First N	amed Inventor	Jacq	ues Dumas
							Art Un	it	1625	
		(Use as	many she	ets as	necessary)		Exami	ner Name	Heidi	L. Reese
◟	Sheet	2		of	37		Attorne	ey Docket Number	BAY	R-0044
ſ						U.S. PA	TENT D	OCUMENTS		
ľ	Examiner	Cite	Do	cument	Number	Publication	n Date	Name of Patentee or Ap Gifed Document		Pages, Columns, Lines, Where Relevant
l	Initials *	No 1	Number -	Kind Co	ode² (if known)	MM-DD-		Cried Documen		Passages or Relevant Figures Appear
I		A38		4,071	524	01-31-	1978	Banitt		
I		A39		4,103	.022	07-25-	1978	Sirrenberg et al		
Г		A40		4,111	.680	09-05-	1978	Yukinaga et al.		

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applica Cited Document	ant of Pages, Columns, Lines, Where Relevant
Initials *	No 1	Number - Kind Code ² (if known)	MM-DD-YYYY	Olice Document	Passages or Relevant Figures Appear
	A38	4,071,524	01-31-1978	Banitt	
	A39	4.103,022	07-25-1978	Sirrenberg et al.	
	A40	4,111,680	09-05-1978	Yukinaga et al.	
	A41	4,111,683	09-05-1978	Singer	
	A42	4,116,671	09-26-1978	Yukinaga et al.	
	A43	4,173,637	11-06-1979	Nishiyama et al.	
	A44	4,173,638	11-06-1979	Nishiyama et al.	
	A45	4,183,854	01-15-1980	Crossley	
	A46	4,212,981	07-15-1980	Yukinaga et al.	
	A47	4,240,820	12-23-1980	Dickore et al.	
	A48	4,279,639	07-21-1981	Okamoto et al.	
	A48a	4,293,328	10-06-1981	Yukinaga et al.	
	A49	4,358,596	11-09-1982	Krüger	
	A50	4,405,644	09-20-1983	Kabbe et al.	
	A51	4,410,697	10-18-1983	Török et al.	
	A52	4,437,878	03-20-1984	Acker et al.	
	A53	4,468,380	08-28-1984	O'Doherty et al.	
	A54	4,473,579	09-25-1984	Devries et al.	
	A55	4,499,097	02-12-1985	Tomoufcik et al.	
	A56	4,511,571	04-16-1985	Böger et al.	
	A57	4,514,571	04-30-1985	Nakai et al.	
	A58	4,526,997	07-02-1985	O'Doherty et al.	
	A59	4,540,588	09-10-1985	Davis et al	
	A60	4,546,191	10-08-1985	Nishiyama et al	
	A61	4,587,240	05-06-1986	Hider et al.	
	A62	4,623,662	11-18-1986	DeVries	
	A63	4,643,849	02-17-1987	Hirai et al.	
	A64	4,740,520	04-26-1988	Hallenbach et al.	
	A65	4,760,063	07-26-1988	Hallenbach et al.	
	A66	4,775,763	10-04-1988	Dalton et al.	
	A67	4,808,588	02-28-1989	King	
	A68	4.820.871	04-11-1989	Kissener et al.	
	A69	4,863,924	09-05-1989	Haga et al.	
	A69a	4,921,525	05-01-1990	Grossman et al.	
	A70	4,973,675	11-27-1990	israel et al.	
	A70a	4,977,169	12-11-1990	Häusermann et al.	
	A71	4.983.605	01-08-1991	Kondo et ai	
	A72	4,985,449	01-15-1991	Haga et al.	
	A72a	4,996,325	02-26-1991	Kristinsson	
Examiner Signature		/Heidi Red	ese/	Date Considered	07/13/2011

This I reference considered, whether or not define; in redefence was NEED's The through values it set is not considered, whether or not define; in redefence was NEED's through values it set is not considered and it considered to study could be compared to suppose of the notification of Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet 3

(Use as many sheets as necessary)

of 37

	Complete if Known
Application Number	10/788,426
Filing Date	March 1, 2004
First Named Inventor	Jacques Dumas
Art Unit	1625
Examiner Name	Heidi L. Reese
Attorney Docket Number	BAYER-0044

			U.S. PATENT D				
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Cited Docum	Applicant of ent	Pages, Columns, Lines, Where Relevant	
Initials *	No 1	Number - Kind Gode ² (if known)	MM-DD-YYYY			Passages or Relevant Figures Appear	
	A73	5,036,072	07-30-1991	Nakajima et al.			
	A74	5.059,614	10-22-1991	Lepage et al.			
	A75	5,063,247	11-05-1991	Sekiya et al.			
	A76	5,098,907	03-24-1992	Kondo et al			
	A77	5,100,883	03-31-1992	Schiehser			
	A78	5,118,677	06-02-1992	Caufield			
	A79	5,118,678	06-02-1992	Kao et al			
	A80	5,120,842	06-09-1992	Failli et al.			
	A81	5,130,331	07-14-1992	Pascual			
	A82	5,151,344	09-29-1992	Abe et al.			
	A83	5,151,413	09-29-1992	Caufield et al.			
	A84	5,162,360	11-10-1992	Creswell et al.			
	A84a	5,177,110	01-05-1993	Oechslein et al.			
	A85	5,185,358	02-09-1993	Creswell et al.			
	A86	5,256,790	10-26-1993	Nelson			
	A87	5,258,389	11-02-1993	Goulet et al.			
	A88	5,270,458	12-14-1993	Lemischka			
	A89	5,283,354	02-01-1994	Lemischka			
	A90	5,312,820	05-17-1994	Ashton et al.			
	A91	5,319,099	06-07-1994	Kamata et al.			
	A92	5,378,725	01-03-1995	Bonjouklian et al.			
	A93	5,399,566	03-21-1995	Katano et al			
	A94	5,423,905	06-13-1995	Fringeli			
	A95	5,429,918	07-04-1995	Seto et al.			
	A96	5,432,468	07-11-1995	Moriyama et al.			
	A97	5,441,947	08-15-1995	Dodge et al.			
	A98	5,447,957	09-05-1995	Adams et al.			
	A99	5,456,920	10-10-1995	Matoba et al			
	A100	5.468.773	11-21-1995	Dodge et al.			
	A101	5,470,882	11-28-1995	Dixon et al.			
	A102	5,480,906	01-02-1996	Creemer et al.			
	A103	5.500.424	03-19-1996	Nagamine et al.			
	A104	5,508,288	04-16-1996	Forbes et al.			
	A105	5,547,966	08-20-1996	Atwal et al.			
	A106	5,559,137	09-24-1996	Adams et al.			
	A107	5,596,001	01-21-1997	Hamanaka			
	A108	5,597,719	01-28-1997	Freed et al			
	A109	5,624,937	04-29-1997	Reel et al.			
Examiner Signature		/Heidi	Reese/	Date Considered		07/13/2011	

Signature Considered UT/10/CUIT PARAMENT Initial Interesting Considered UT/10/CUIT PARAMENT Initial Interesting Considered UT/10/CUIT PARAMENT Initial Interesting Considered Include copy of this form with next communication to applicant "Applicant" suspect authors designation number (optional) "See Redis Codes of USFOP Patent Documents and war applicant of the Emperor must precede the service of the Comment of the Parameter of the Emperor must precede the service of the Comment of the Parameter of the Emperor must precede the service of the patent document, the three height and parameter of the Emperor must precede the service of the patent document, the three three parameters are serviced in the document of the patent document, the Parameter of the Emperor must precede the service of the patent document, the Parameter of the Emperor must precede the service of the patent document, the Parameter of the Emperor must precede the service of the patent document, the Parameter of the Emperor must precede the service of the patent document of the patent document of the Parameter of t Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

Sheet 4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 37

		Complete if Known
	Application Number	10/788,426
	Filing Date	March 1, 2004
	First Named Inventor	Jacques Dumas
	Art Unit	1625
	Examiner Name	Heidi L. Reese
ī	Attorney Docket Number	BAYER-0044

			U.S. PATENT D	OCUMENTS			
Examiner Cite Document Number Publication Initials No Number View Code (International Number View Code)				Name of Patentee or A Cited Docume	Applicant of ent	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials -	No .	Number - Kind Gode ² (if known)	MM-DD-TTTT			Figures Appear	
	A110	5,656,612	08-12-1997	Monia Adams et al.			
	A111	5,658,903	08-19-1997				
A111		5,667,226	09-16-1997	Janich			
	A112	5,696,138	12-09-1997	Olesen et al.			
	A113	5,698,581	12-16-1997	Kleemann et al			
	A114	5,710,094	01-20-1998	Minami et al.			
	A115	5,721,237	02-24-1998	Myers et al			
	A116	5,726,167	03-10-1998	Dodge et al.			
	A117	5,747,498	05-05-1998	Schnur et al.			
	A118	5,773,459	06-30-1998	Tang et al.			
	A119	5,777,097	07-07-1998	Lee et al.			
	A120	5,780,262	07-14-1998	Brent et al.			
	A121	5,780,483	07-14-1998	Widdowson et al.			
	A122	5,783,664	07-21-1998	Lee et al.			
	A123	5,786,362	07-28-1998	Krongrad			
	A123a	5,801,794	09-01-1998	Lehureau et al.			
	A124	5,807,876	09-15-1998	Armistead et al.			
	A125	5,807,891	09-15-1998	Bold et al.			
	A126	5,803,080	09-15-1998	Bell et al.			
	A127	5,814,646	09-29-1998	Heinz et al McDonnell et al. Lee et al.			
	A128	5,869,043	02-09-1999				
	A129	5,871,934	02-16-1999				
	A130	5,886,044	03-23-1999	Widdowson et al.			
	A131	5,891,895	04-06-1999	Shiraishi et al.			
	A132	5,908,865	06-01-1999	Doi et al.			
	A133	5,919,773	07-06-1999	Monia et al			
	A134	5,929,250	07-27-1999	Widdowson et al.			
	A135	5,955,366	09-21-1999	Les et al.			
	A136	5,965,573	10-12-1999	Petrie et al.			
	A137	6,004,965	12-21-1999	Breu et al.			
	A138	6,005,008	12-21-1999	Widdowson et al.			
	A139	6,015,908	01-18-2000	Widdowson et al.			
	A140	6,017,692	01-25-2000	Brent et al.			
	A141	6,020,345	02-01-2000	Vacher et al.			
	A142	8,022,884	02-08-2000	Mantlo et al.		1	
	A143	6,025,151	02-15-2000	Peterson			
	A144	6,033,873	03-07-2000	McDonnell et al.			
	A145	6,040,339	03-21-2000	Yoshida et al.			
Examiner Signature		/Heidi Reese/	1	Date Considered		07/13/2011	

Signature (PIULI INVESE) Considered

FIGURI INVESE (PIULI INVESE) Considered

FIGURI INVESE (PIULI INVESE) Considered

FIGURIA INVESTIGATION IN THE PIULI INVESE (PIULI INVESTIGATION IN THE PIULI IN THE PIULI INVESTIGATION IN THE PIULI IN Alexandria, VA 22313-1450.

PTO/SB/08a (11-07)
Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE prespond to a collection of information.

Substitute	for form 1449A/PTC)		Complete if Known			
				Application Number	10/788,426		
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
STAT	TEMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625		
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Sheet	Sheet 5		37	Attorney Docket Number	BAYER-0044		

		Document Number	Dat Senter Bets	Name of Patentee or		B O.I
Examiner Initials *	No 1	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Docum	ent	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
	A110	5,656,612	08-12-1997	Monia		
	A111	5,658,903	08-19-1997	Adams et ai.		
	A146	6,043,374	03-28-2000	Widdowson et al		
	A147	6,080,763	06-27-2000	Regan et al.		
	A148	6,093,742	07-25-2000	Salituro et al		
	A149	6,103,692	08-15-2000	Avruch et al.		
	A150	6,114,517	09-05-2000	Monia et al		
	A151	6,130,053	10-10-2000	Thompson et al.		
	A152	6,133,319	10-17-2000	Widdowson		
	A153	6,136,779	10-24-2000	Foulkes et al.		
	A154	6,143,764	11-07-2000	Kubo et al.		
	A155	6,147,107	11-14-2000	Dent et al.		
	A156	6,147,116	11-14-2000	Barbachyn et al.		
	A157	6,150,415	11-21-2000	Hammock et al.		
	A157a	6,159,901	12-12-2000	Kanno et al		
	A158	6,174,901	01-16-2001	Mantlo et al.		
	A159	6,177,401	01-23-2001	Ullrich et al.		
	A160	6,178,399	01-23-2001	Takebayashi et al		
	A161	6,180,631	01-30-2001	McMahon et al.		
	A162	6,180,675	01-30-2001	Widdowson et al.		
	A163	6,187,799	02-13-2001	Wood et al.		
	A164	6,193,965	02-27-2001	Karin et al.		
	A165	6,204,267	03-20-2001	Tang et al		
	A166	6,210,710	04-03-2001	Skinner		
	A167	6,211,373	04-03-2001	Widdowson et al		
	A168	6,218,539	04-17-2001	Widdowson		
	A169	6,228,881	05-08-2001	Regan et al.		
	A170	6,235,764	05-22-2001	Larson et al.		
	A170a	6,236,125	05-22-2001	Oudet et al		
	A171	6,242,601	06-05-2001	Breu et al.		
	A172	6,262,113	07-17-2001	Widdowson et al.		
	A173	6,271,261	08-07-2001	Widdowson		
	A174	6,294,350	09-25-2001	Peterson		
	A175	6,297,381	10-02-2001	Cirillo et al.		
	A176	6,310,068	10-30-2001	Böttcher et al.		
	A177	6,316,462	11-13-2001	Bishop et al.		
	A178	6,319,921	11-20-2001	Cirillo et al.		
	A179	6,329,415	12-11-2001	Cirillo et al.		
xaminer		/Heidi Reese/		Date Considered	(07/13/2011

"EXAMINE! In district considered, whether or not callow in a noticement with IEEE and their linear linear linear and extended to the control of their members of the control of their linear and extended to open control of their linear linear

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substi	Substitute for form 1449A/PTO						Complete if Known		
INFORMATION DISCLOSURE						Applic	ation Number	10/7	788,426
						Filing Date		Mar	ch 1, 2004
ST	STATEMENT BY APPLICANT					First N	lamed Inventor	Jaco	ques Dumas
						Art Ur	nit	162	5
	(Us	as many sh	eets as	necessary)		Exam	iner Name	Heio	di L. Reese
Sheet	Sheet 6 of 37				Attorn	ey Docket Number	BAY	/ER-0044	
	U.S. PAT						OCUMENTS		
							Alomo of Dotonton or An-	baout of	

			U.S. PATENT I				
Examiner Cite Initials * No		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicar Cited Document	nt of Pages, Columns, Lines, Where Relevant Passages or Relevant		
		Number - Kind Gode ² (if known)			Figures Appear		
	A180	6,333,341	12-25-2001	Mantlo et al.			
	A181	6,339,045	01-15-2002	Kanno et al			
	A182	6,344,476	02-05-2002	Ranges et al.			
	A183	6,352,977	03-05-2002	Astles et al			
	A184	6,358,525	03-19-2002	Guo et al.			
	A185	6,358,945	03-19-2002	Breitfelder et al.			
	A186	6,361,773	03-26-2002	Lee et al.			
	A187	6,372,773	04-16-2002	Regan			
	A188	6,372,933	04-16-2002	Baine et al			
	A189	6,380,218	04-30-2002	Marfat et al.			
	A190	6,383,734	05-07-2002	Marshall et al.			
	A191	6,387,900	05-14-2002	Pevarello et al.			
	A192	6,391,917	05-21-2002	Petrie et al			
	A193	6,403,568	06-11-2002	Hayakawa et al.			
	A194	6,414,011	07-02-2002	Hogenkamp et al.			
	A195	6,444,691	09-03-2002	Oremus et al.			
	A196	6,448,079	09-10-2002	Monia et al.			
	A197	6,479,519	11-12-2002	Astles et al			
	A198	6,492,393	12-10-2002	Breitfelder et al.			
	A199	6,495,331	12-17-2002	Gelfand et al.			
	A200	6,500,863	12-31-2002	Jin et al.			
	A201	6,511,800	01-28-2003	Singh			
	A202	6,511,997	01-28-2003	Minami et al.			
	A203	6,521,407	02-18-2003	Warenius et al			
	A204	6,521,592	02-18-2003	Ko st al.			
	A205	6,524,832	02-25-2003	Kufe et al.			
	A206	6,525,046	02-25-2003	Cirillo et al.			
	A207	6,525,065	02-25-2003	Caldwell et al.			
	A208	6,525,091	02-25-2003	Robinson et al.			
	A209	6,583,282	06-24-2003	Zhang et al.			
	A210	6,608,052	08-19-2003	Breitfelder et al.			
	A211	6,617,324	09-09-2003	Naraian et al.			
	A212	6,635,421	10-21-2003	Klagsbrun et al.			
	A213	6,653,320	11-25-2003	Hayakawa et al.			
	A214	8,858,983	12-02-2003	Firestone et al.			
	A215	6,673,777	01-06-2004	Tracey et al.			
	A216	6,689,560	02-10-2004	Rapp et al.			
	A217	6,797,323	09-28-2004	Kubo et al.			
Examiner Signature		/Heidi Res		Date Considered	07/13/2011		

/Heidi Reese/

Signature Considered

FixANINER Initial inference considered, whether or not classion is in conformance with MEP 500 Draw line through classion in no in conformance and not considered include capy of this form with next communication to applicant. "Applicant" suapse classion designation number (optional). "See Kinds Codes of USFO Patent Documents are waited to the property of the patent of the patent document, but the book lens of WIPO Standard ST 3.1" For Jupanese patent document, in reduction of the year of the regin of the Emperor must proceds the serial number of the patent document, the three Applicants are part of the patent document, the way of the patent document is the patent document, the way of the patent document is proceed by the patent document of the patent document is proceed by the patent of the patent document is proceed by the patent of the patent document is proceed by the patent of the patent document is proceed by the patent of the patent document is proceed by the patent of the patent document is proceed by the patent of the patent of the patent document is proceed by the patent of the patent of the patent document is proceed by the patent of the pate Alexandria, VA 22313-1450.

U.S. Patient and Trademark Office 1). S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are recarded to recorded to accelerate of Harmonton trests to critical as valid CMS comits untreSubstitute for form 1449APTO
Complete If Known
Amelioration Municipe
1,1709,476

Gubantute	I I I I I I I I I I I I I I I I I I I	,			Complete ii Known	
			Application Number	10/788,426		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Sheet 7 01 37	CLOSURE	Filing Date	March 1, 2004			
STATEMENT BY APPLICANT				First Named Inventor	Jacques Dumas	
				Art Unit	1625	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		necessary)	Examiner Name	Heidi L. Reese		
Sheet	7	of	37	Attorney Docket Number	BAYER-0044	

U.S. PATENT DOCUMENTS Document Number Name of Patentee or Applicant of Publication Date Cited Docu Pages, Columns, Lines, Where Relevant MM-DD-YYYY Passages or Relevant Number - Kind Code² (if known) Figures Appear A217a 6,958,333 10-25-2005 Hayama et al. A218 Kufe et al A219 7.235.576 06-26-2007 Riedi et al A220 7 253 286 08-07-2007 Funahashi et al A221 7 307 071 12-11-2007 Lyons et al A222 7.329.670 02-12-2008 Dumas et al A223 7.351.834 04-01-2008 Riedl et al Dumas et al A225 7.517.880 04-14-2009 Miller et al A226 7.528.255 05-05-2009 Riedi et al A226a 7 547 665 08-16-2009 Hoelzemann et al A227 7 557 190 07-07-2000 Scott at all A227a 7,605,261 10-20-2009 Deprez et al A227 7.612.092 11-03-2009 Funahashi et al b A228 7.678.811 03-16-2010 Dumas et al B1 2001/0006975 07-05-2001 Wood et al R2 2001/0011135 Riedl et al **B3** 2001/0011136 08-09-2001 Rigdl et al B4 2001/0016659 08-23-2001 Riedl et al. 85 Riedl et al 86 Riedi et al. 2001/0034447 10-25-2001 B7 2001/0038842 11-08-2001 Achen et al В8 03-28-2002 Ptasznik et al. 89 04-11-2005 2002/0042517 Uday et al B10 2002/0062763 05-30-2002 Macholdt et al. B11 McMahon et al B12 2002/0065296 05-30-2002 B13 2002/0082255 06-27-2002 Fastwood R14 2002/0085857 07-04-2002 Kim et al. **B15** 2002/0025950 07-04-9005 Hashimoto et al. B16 08-01-2002 Ranges et al. B16a 2002/0111495 Magee et al. B17 2002/0128321 09-12-2002 Widdowson et al B18 2002/0137774 09-28-2002 Riedt et at B19 2002/0161014 10-31-2002 Sadhu et al

EXAMATE: This I reference considered, whether or not delation in a notiferance with MEPS 000 flow line through delation if not in conformance and not considered include copy of this form with near communication to applicate. Replication suspect collection designation marked proteins—like self-and colored to MEPS 00104. Extend Colored

Date

Considered

07/13/2011

/Heidi Reese/

Examiner

Signature

This collection of Information is required by 37 CFR 197 and 188. The information is required to obtain or return a bornelit by the public wheth is to life (and by the USPT) to proceed an experience Confedental by an experience by 2015 CFR 197 and 21 CFR 11.1 The collection is estimated to take 2 hower to expensive, modified gradient, preparing preparing preparing to the collection of th

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons ar to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/788 426 INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 8 of 37 BAYER-0044 Attorney Docket Number

	-	0, 3,			TE11-0044
			U.S. PATENT I		
Examiner Initials *	Cite No	Document Number Number - Kind Gode ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	B21	2002/0165349	11-07-2002	Kirsch et al.	
	822	2002/0165394	11-07-2002	Dumas et al	
	B23	2002/0173507	11-21-2002	Santora et al.	
	B24	2002/0188027	12-12-2002	Robinson et al.	
	B25	2002/0197256	12-26-2002	Grewal	
	B26	2003/0069284	04-10-2003	Keegan et al.	
	B26e	2003/0105091	06-05-2003	Riedl et al.	
	B27	2003/0125359	07-03-2003	Lyons et al.	
	B28	2003/0130309	07-10-2003	Moss et al.	
	B29	2003/0144278	07-31-2003	Reidl et al.	
	B30	2003/0157104	08-21-2003	Waksal	
	B30a	2003/0139605	07-24-2003	Ried! et al	
	B31	2003/0181442	09-25-2003	Riedl et al	
	B32	2003/0207870	11-06-2003	Dumas et al.	
	B33	2003/0207872	11-06-2003	Reidl et al.	
	B34	2003/0207914	11-06-2003	Dumas et al.	
	B34a	2003/0216396	11-20-2003	Dumas et al.	
	B35	2003/0216446	11-20-2003	Dumas et al.	
	B36	2003/0232400	12-18-2003	Radka et al.	
	B37	2003/0232765	12-18-2003	Carter et al.	
	B37a	2004/0023981	02-05-2004	Dumas et al.	
	B38	2004/0052880	03-18-2004	Kobayashi et al	
	B39	2004/0096855	05-20-2004	Stratton et al.	
	B40	2004/0147541	07-29-2004	Lane et al.	
	B41	2004/0192770	09-30-2004	Kozikowski et al	
	B42	2004/0197256	10-07-2004	Rogers et al.	
	B43	2004/0209905	10-21-2004	Kubo et al	
	B43a	2004/0224937	11-11-2004	Furness et al.	
	B44	2004/0229937	11-18-2004	Dumas et al.	
	B45	2004/0235829	11-25-2004	Scott et al.	
	B46	2005/0032798	02-10-2005	Boyer et al	
	B47	2005/0038031	02-17-2005	Dumas et al.	1
	B48	2005/0038080	02-17-2005	Boyer et al.	
	B49	2005/0059703	03-17-2005	Withelm et al.	
	B49a	2005/0069963	03-31-2005	Lokshin et al.	1
	B49b	2005/0096344	05-05-2005	Fraley et al.	
	B49c	2005/0175737	08-11-2005	Knobel	1
	B50	2005/0256174	11-17-2005	Wood et al	
Examiner Signature		/Heidi Rees	e/	Date Considered	07/13/2011

ignature /He/GI Heese/

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered

"EXAMINER Inhal if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation in or in conformance with MPEP 809. Draw line through citation is not in conformance with MPEP 809. Draw line through citation is not in conformance with MPEP 809. Draw line through citation is not in conformance with MPEP 809. Draw line through citation is not income and in citation is not income and income and in citation is not income and income

"EXAMINE! In this if reference considered, whether or not dation is in conformance with MEPE 900. Dark limit integral, a chain if not in conformance and not considered include copy of this core with next communication to application." Adjustment usages actional recognition number (optional). "See Menda Code of USETO Pater Note December at a chain of the pater of the Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	Substitute for form 1449A/PTO						Complete if Known			
						Appl.	ication Number	10/7	10/788,426	
INF	DRMA	NOITA	DIS	CLOS	JRE	Filing) Date	March 1, 2004		
STA	TEME	ENT B	YA	PPLICA	ANT	First Named Inventor			ques Dumas	
						Art U	Init	162	5	
	(Use a	s many she	ets as	necessary)		Examiner Name			li L. Reese	
Sheet 9 of 37					Attor	ney Docket Number	BAY	ER-0044		
					U.S. PAT	ENT	OCUMENTS			
	Cite	Document Number Number - Kind Gode ² (if known)		Publication	Date	Name of Patentee or Applic Cited Document	ant of	Pages, Columns, Lines, Where Relevant		
	No 1			MM-DD-Y		Only Document		Passages or Relevant Figures Appear		
	B51	200	05/028	8286	12-29-2	005	Flynn et al.			
	B52	200	06/005	8358	03-16-2	306	Dumas et al			
	B52a	200	06/024	1301	10-26-2	006	Hoelzemann et al.			
	B52b	200	06/028	1762	12-14-21	006	Stashle et al.			
	B53	200	06/00 7	8617	04-13-2	006	Schueckler			
	B54	200	06/021	1738	09-21-2	306	Mitchell et al.			
	B55	200	06/023	4931	10-19-2	006	Biggs. III et al.			
	B56	200	06/024	7186	11-02-2	306	Carter et al.			

Examiner Signature		/Heidi Reese/		Date Considered	07/13/2011
	888	2010/0063033	03-11-2010	Wood et al.	
	B86	2009/0306020	12-10-2009	Scheuring et al	
	B85	2009/0227637	09-10-2009	Weber et al.	
	B84a	2009/0221010	09-03-2009	Elting et al.	
	B84	2009/0215835	08-27-2009	Wilhelm	
	B82	2009/0192127	07-30-2009	Scheuring et al	
	B80	2009/0118268	05-07-2009	Riedi et al.	
	B79	2009/0093526	04-09-2009	Miller et al.	
	B78	2009/0068146	03-12-2009	Wilhelm	
	B77b	2008/0311604	12-18-2008	Etting et al.	
	B77a	2008/0311601	12-18-2008	Eiting et al.	
	B77	2008/0300281	12-04-2008	Dumas et al.	
	B76	2008/0269265	10-30-2008	Miller et al.	
	B74	2008/0242707	10-02-2008	Schuckler et al.	
	B73	2008/0227828	09-18-2008	Dumas et al.	
	B72	2008/0214545	09-04-2008	Lee et al.	
	B71	2008/0194580	08-14-2008	Dumas et al	
	B70	2008/0153823	06-26-2008	Riedi et al.	
	B69	2008/0108672	05-08-2008	Riedl et al.	
	B67	2008/0045589	02-21-2008	Kelley	
	B65	2008/0032979	02-07-2008	Riedl et al.	
	B64	2008/0027061	01-31-2008	Riedl et al.	
	B63	2008/0009527	01-10-2008	Dumas et al.	
	862	2007/0265315	11-15-2007	Dumas et al	
	B61	2007/0244120	10-18-2007	Dumas et al	
	B60	2007/0178494	08-02-2007	Elting et al.	
	858	2007/0105142	05-10-2007	Wilhelm	
	B57	2007/0020704	01-25-2007	Withelm et al.	

EXAMINER Initial if elerence considered, whether or not clatton is in conformance with MFEP 600 Draw line through citation if not in conformance and not considered include copy of this form with not communication to applicant. Applicant is used to elegate the conformance of the

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons to respond to a collection of information unless it contains a valid OMB control number

	_	Cridor vio i aporno	TT T IDOO	Soci From Cr. 1000, Fio pordorio di	o roquiros to reciporas to a concentra rom	IGHT GOOD TO TOO TOO TOO TOO TOO TOO TOO TOO T			
1	Substitute	for form 1449A/PTC)		Complete if Known				
					Application Number	10/788,426			
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004			
	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas			
					Art Unit	1625			
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese			
7	Sheet	10	of 37		Attorney Docket Number	BAYER-0044			

		FOREIGN PA	TENT DOCU	IMENTS			
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	C1	WO-90/02112	03-08-1990	The Nutrasweet Company			
	C2	WO-92/03413	03-05-1992	Rhone-Roulenc Rorer Limited et al.			
	СЗ	WO-92/05179	04-02-1992	American Home Products Corporation			
	C4	WO-93/04170	03-04-1993	The United States of America represented by The Secretary, Department Of Health And Human Services			
	C5	WO-93/18028	09-16-1993	SmithKline Beecham PLC et al.			
	C6	WO-93/24458	12-09-1993	Pfizer Inc. et al.			
	C7	WO-94/02136	02-03-1994	SmithKline Beecham Corp. et al.			
	C8	WO-94/02485	02-03-1994	SmithKline Beecham Corp. et al.			
	C9	WO-94/04541	03-03-1994	The UpJohn Co. et al.			
	C10	WO-94/14801	07-07-1994	SmithKline Beecham PLC et al.			
	C11	WO-94/18170	08-18-1994	SmithKline Beecham PLC et al			
	C12	WO-94/22807	10-13-1994	Neu-Rosearch, A/S et al.			
	C13	WO-94/23755	Board of Regents 10-27-1994 of the University : Nebraska				
	C14	WO-94/25012	11-10-1994	SmithKline Beecham PLC et al.			
	C15	WO-95/02136	01-19-1995	Mannesmann Akteingesellschaft		abs	
Examiner Signature		/Heidi Reese/	Date Conside				

Companies that I reference considered, whether to not delition is a conformance with MET 0x00 three fine through delition is in a conformance with MET 0x00 three fine through delition is not in conformance with MET 0x00 three fines through delition is used conformance with mean commission to supplicate its supercentation descipation or interfered forced in SEP 0x10 with the commission as a recommendation of the fine of the supercentation of the supercentatio Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute	for form 1449A/PTC		au i na uri i aau, no paraura ar	Complete if Known			
				Application Number	10/788,426		
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
STAT	TEMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625		
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Sheet	11	of	37	Attorney Docket Number	BAYER-0044		

Sheet	11	of 37	Atto	rney Docke	t Number	BAY	ER-0044	
		FOREIGN	PATEN	IT DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if kno		ublication Date I-DD-YYYY	Applica	Patentee or ant of Cited current	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C16	WO-95/02591	01	-26-1995	SmithKlir Beechan Corporat	1		
	C17	WO-95/07922	03	-23-1995	SmithKlir Beechan Corporat	1		
	C18	WO-95/13067	05	-18-1995	SmithKlir Beechan Corporat	1		
	C19	WO-95/14023	05	-26-1995	Aooott La	aboratories		
	C20	WO-95/16691	06	-22-1995	Sandoz I	.td. et al.		
	C21	WO-95/19169	07	-20-1995	Sugen, Ir	no.		
	C22	WO-95/31451	11	-23-1995	Smithklin Beechan Corporat	1		
	C23	WO-95/33458	12	-14-1995	Smithklin Beecharr Corporat	1		
	C24	WO-95/33460	12	-14-1995	Smithxlin Beecharr Corporat	ion et al.		
	C25	WO-96/02112	01	-25-1996	Thornson al.	-CSF et		abs
	C26	WO-96/10559	04	-11-1996	Fujisawa 11-1996 Pharmaceutical Co Ltd			
	C27	WO-96/13632	05	-09-1996	Novo No et al.	rdisk A/S		
	C28	WO-96/25157	08	-22-1996	Smith Kli Beechan Corporat	1		
	C29	WO-96/40673	12	-19-1996	Sugen, Ir	nc.		
	C30	W0-96/40675	12	-19-1996	Sugen. In	10.		
	C31	WO-96/41807	12	-27-1996	Sandoz I	.td. et al		
	C32	WO-97/03069	01	-30-1997	Glaxo Gr Limited e			
	C33	WO-97/09973	03	The Regents of 3-20-1997 The University of California et al.				
	C34	WO-97/17267	05	-15-1997	et al.	ntycke AB		
	C35	WO-97/17329	05	-15-1997	Kırın Bee Kabushil			abs
Examiner Signature		/Heidi Reese/		Date Consid	lered		07/13/20	11

EXAMINER Initial if reference considered, whether or not clustion is in conformance with MFP 600. Draw line through cluston if not in conformance and not considered include copy of this form with next communication to applicant. Applicant is value, cluston designation number (spicting). See Minist Code of USPTO Patent Documents are value of the communication of the property of the region of the Engine Interpretation of

Under the Paperwork Reduction Act of 1995, no persons are reed to respond to a collection of information unless it contains a valid OMB control number

Complete if Known			
Application Number	10/788,426		
Filing Date	March 1, 2004		
First Named Inventor	Jacques Dumas		
Art Unit	1625		
Examiner Name	Heidi L. Reese		
Attorney Docket Number	BAYER-0044		
	Filing Date First Named Inventor Art Unit Examiner Name		

Sheet	12	or	3/	Attorn	ey Docke	t Number	BAY	ER-0044	
			FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent	Document Number ⁴ - Kind Code ⁶ (if known)		lication Date D-YYYY	Applica	Patentee or ant of Cited cument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C36	,	WO-97/297 43	08-2	1-1997	Smith Kli Beechan Corporat	1		
	C37		WO-97/30992	08-2	8-1997	Bristol-M Squibb C			
	C38	,	WO-97/34146	09-1	8-1997	The Gen Hospital Corporat			
	C39	,	WO-97/40028	10-3	0-1997	Vertex Pharmac Incorpora	ated		
	C40		WO-97/40842	11-0	6-1997	Eli Lilly a Company	ind y et al.		
	C41	,	WO-97/45400	12-0	4-1997	Neu-Ros et al.	earch A/S		
	C42	,	WO-97/49399	12-3	1-1997	SmithKlir Beecharr Corporat	n		
	C43	,	WO-97/49400	12-3	1-1997	SmithKlis Beechan Corporat	n		
	C44		WO-98/17207	04-3	0-1998	Synthes et al.	AG Chur		
	C45		WO-98/17267	04-3	0-1998	et al.	netics, Inc.		
	C46		WO-98/20868	05-2	2-1998	Research	for Medical h		
	C47		WO-98/22103	05-2	8-1998	al.	Limited et		
	C48	,	WO-98/22432	05-2	8-1998	Yamano Pharmac Co., Ltd.	eutical		abs
	C49		WO-98/32439	07-3	0-1998	SmithKlis Beechan Corporat	1		
	C50	WO-98/34929 WO-98/45268		08-13-1998 SmithKline Beecham Corporation et al. 10-15-1998 Inc., et al.					
	C51								
C52		WO-98/49150		11-05-1998		Takeda (Industrie: al.	Chemical s, Ltd. et		
Examiner Signature		J	Heidi Reese/	Date Consid		ered		07/13/2011	

Signature "EXAMPLE Index of interesco considered, whether or not citation is in conformance with MEEP trap Draw line through subsort first in conformation to applicate if replicates in user called the designation manufactor (septicated in the properties of the form white the communication to applicate if replicates in user called the segment on marble (operation)." See finded Coolered USPTO Patient Description and the conformation of the conformation o

The collection of infollowable deplication of your Access that the property of Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are requi

	Substitute	for form 1449A/PTC)			Complete if Known	_
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STATEMENT BY APPLICANT		PPLICANT	First Named Inventor	Jacques Dumas		
					Art Unit	1625	
(Use as many sheets as necessary)					Examiner Name	Heidi L. Reese	
	Sheet	13	of	37	Attorney Docket Number	BAYER-0044	

		FOREIGN PA	TEN	r Docu	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ⁹ - Number ⁴ - Kind Code ⁶ (<i>if known</i>)		olication Date DD-YYYY	Applio Do	f Patentee or ant of Cried curnent	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C53	WO-98/52558	11-2	6-1998	Bayer Co et al.	orporation		
	C54	WO-98/52559	11-2	6-1998	Bayer Co et al.	orporation		
	C55	WO-98/52937	11-2	6-1998	G.D. Sea Coet al			
	C56	WO-98/52941	11-2	6-1998	G D, Sea Co. et al.			
	C57	WO-98/56377		7-1998	SmithKli Beechan Corporat	n		
	C58	WO-99/00357		7-1999	Vertex Pharmac Incorpora	ated		
	C59	WO-99/00370	01-07-1999 Kurehs Kagaku Kogyo Kabushiki Kaisha		abushiki		abs	
	C60	WO-99/20617		9-1999	Pharmacia & UpJohn Company et al.			
	C61	WO-99/21835		6-1999	Co., Ltd. et al.			
	C62	WO-99/23091	05-1	4-1999	Boehringer Ingelheim Pharmaceuticals, Inc.			
	C63	WO-99/24035	05-2	0-1999	Bristol-M Squibb C			
	C64	WO-99/24398	05-2	0-1999	Zeneca I al.	imited et		
	C65	WO-99/24835	05-2	0-1999	Advance Technolo Materials	gy		
	C66	WO-99/26657	06-0	3-1999	Medical of South et al.	University Carolina		
	C67	WO-99/28305	06-1	0-1999	E.I. Dupo Nemours Compan	: &		
	C68	WO-99/32106	07-0	1-1999		orporation		
	C69	WO-99/32109		1-1999	Bristol-M Squibb C	Company		
	C70	WO-99/32110		1-1999	Bayer Corporation			
$\overline{}$	C71 WO-99/32111		07-0	1-1999	Bayer Co	orporation		
Examiner /Heidi Reese/ Signature				Date Consid	ered	07	/13/2011	

EXAMINENT Initial of reference considered, whether or not dation is in conformance with MFPE 600 Draw line through catalon if not in conformance and not considered include copy of the form with not communication to applicant. Applicant's usuage catalons designation number (spotcing). See finds Code of USFTO Patent Documents are used to the communication of the com

to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are requi

1	Substitute	for form 1449A/PTC)			Complete if Known	•
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
┖	Sheet	14	of	37	Attorney Docket Number	BAYER-0044	

		FOREIGN PA	TENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ² (<i>if known</i>)		ication late D-YYYY	Applica	Patentee or ant of Cited current	Pages, Columns, Lines, Where Relevant Passages or Relevant Flgures Appear	T ⁶
	C72	WO-99/32436	07-0	1-1999	Bayer Co	orporation		
	C73	WO-99/32437	07-0	1-1999	Slovako- A.S. et a			
	C74	WO-99/32455	07-0	1-1999	Bayer Co	orporation		
	C75	WO-99/32463	07-0	1-1999		orporation		
	C76	WO-99/33458	07-0	3-1999	Dailchi Pharmac Co., Ltd.	et al.		abs
	C77	WO-99/35132	07-1	5-1999	Glaxo Gr Limited e			
	C78	WO-99/40673	08-1	2-1999	Moving Noting Noting (S.A.) et	naies		abs
	C79	WO-99/58502	11-1	8-1999		ated et al.		
	C80	WO-99/62890	12-0	9-1999	et al.	oducts inc.		
	C81	WO-00/12497	03-0	9-2000	Scios Inc	c. et al.		
	C82	WO-00/17175	03-3	0-2000	Vertex Pharmac Incorpora	euticals ated et al		
	C83	WO-00/19205	04-0	8-2000	Advance Research Technologi Institute	h and		
	C84	WO-00/26203	05-1	1-2000	al.	ia & S.P.A. et		
	C85	WO-00/27414	05-1	3-2000	BASF Aktienge et al	sellschaft		
	C86	WO-00/31238	06-0	2-2000	Genetica	, Inc. et al.		
	C87	WO-00/34303	06-1	5-2000	Isis Pharmac Inc. et al	euticals,		
	C88	WO-00/35454	06-23	2-2000	Du Pont Pharmac Compan			
	C89	WO-00/35455	06-2	2-2000	Telik. Inc			
	C90	WO-00/39101	07-0	8-2000	Limited e			
	C91	WO-00/39116	07-0	8-2000	Teikoku MFG Co	Hormone Ltd.		abs
Examiner Signature	;	/Heidi Reese/		Date Consid	ered		07/13/2011	

"In North Trobust Today of reference or "In North Trobust Trob Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are requi ed to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC)		Complete if Known				
				Application Number	10/788,426			
			CLOSURE	Filing Date	March 1, 2004			
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas			
				Art Unit	1625			
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese			
Sheet	15	of	37	Attorney Docket Number	BAYER-0044			

		FOREIGN PA	TENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁶ (if known)		ication late D-YYYY	Applica	f Patentee or ant of Cited current	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C92	WO-00/41698	07-2	0-2000	Bayer Co et al.	orporation		
	C93	WO-00/42012	07-2	07-20-2000		orporation		
	C94	WO-00/43366	07-2	7-2000	Kirin Bee Kabushil			abs
	C95	WO-00/43384	07-2	7-2000	Boehring Ingelheir Pharmad Inc			
	C96	WO-00/47577	08-1	7-2000	al	n PLC et		
	C97	WO-00/50425	08-3	1-2000	Boehring Ingelheir Pharmad Inc.			
	C98	WO-00/55139	09-2	1-2000	Boehring Ingelheir Pharmad Inc.	ger n ceuticals,		
	C99	WO-09/55152	09-2	1-2000	Boehring Ingelheir Pharmad Inc	n		
	C100	WO-00/56331		09-23-2000		ceuticals ated et al.		
	C101	WO-00/71506	11-3	0-2000	Telik, Inc			
	C102	WO-00/71532	11-3	0-2000	Pfizer Pr Inc. et al			
	C103	WO-01/04115	01-1	3-2001	Inc.			
	C104	WO-01/07411	02-0	1-2001	Banyu Pharmac Co., Ltd.			abs
	C105	WO-01/09088	02-0	B-2001	Kırın Bee Kabushil et al.	ki Kaisha		
	C106	WO-01/12188	02-2	2-2001	Pharmac UpJohn : al.	cia & S.P.A. et		
Examiner Signature		/Heidi Reese/		Date Consid	ered	07/13	/2011	

Signature

Exclusive India 4 indexence considered, whether or not californ in a conformance with MEPF 600. Draw line in tough, dataset if not in conformance and not considered a management of the region of the proper management of the region of the region of the proper management of the region of the region of the proper management of the region of the Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number

	Substitute	for form 1449A/PTC)		ICANT First Named Inventor Jacques Dumas Art Unit 1625			
					Application Number	10/788,426		
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
	STAT	ATEMENT BY APPLICANT		PPLICANT	First Named Inventor	Jacques Dumas		
					Art Unit	1625		
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Ū	Sheet	16	of	37	Attorney Docket Number	BAYER-0044	_	

		FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if known)		lication Date D-YYYY	Applica	Patentee or ant of Cited cument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
	C107	WO-01/36403	05-2	5-2001	Boehring Ingelheir Pharmac Inc. et al	n seuticals,		
	C108	WO-01/47892	07-0	5-2001	America Products Corporat	ion		
	C109	WO-01/54723	08-0	2-2001	Science al.	ook Health Center et		
	C110	WO-01/54727	08-0	2-2001	Group, In	Kampen nc. et al.		
	C111	WO-01/57008	08-0	9-2001	BASF Aktienge et al.	sellachaft		
	C112	WO-01/63403	08-3	0-2001	Sun Mia Inc	rosystems,		
	C113	WO-01/86099	09-1	3-2001	Astra Ze et al.	neca AB		
	C114	WO-01/66540	09-1	3-2001	SmithKli Beechan al.	ne n P.L.C. et		
	C114a	WO-01/80843	11-0	1-2001	Superge al	n, Inc. et		
	C115	WO-02/06382	01-2	4-2002	General Compan			
	C116	WO-02/07747	01-3	1-2002	Joslin Di Center, I			
	C117	WO-02/07772	01-3	1-2002	Boehring Ingelheir Pharmad Inc.	n		
	C118	WO-02/10141	02-0	7-2002	Pfizer Pr Inc. et al			
	C119	WO-02/14281	02-2	1-2002	Cochran	et al.		
	C120	WO-02/14311	02-2	1-2002	Amgen I			
	C121	WO-02/18346	03-0	7-2002	Pfizer Pr Inc. et al			
	C122	WO-02/24635	03-2	8-2002	Fujisawa Pharmad Co , Ltd	eutical		
	C123	123 WO-02/25286		8-2002		sident and of Harvard		
	C124	WO-02/32872	04-2	5-2002	Eisai Co	., Ltd.		abs
	C125	WO-02/40445		3-2002	Novo No	rdisk A/S		
	C126	WO-02/42012	05-3	0-2002	Brill			
Examiner Signature	xaminer /Heidi Reese/			Date Consid	dered		07/13/2011	

The control of the co

and submitting the completed application from the teSPTO. The will very depending upon the individual case. Any comments on the amount of the improvement of the comments of the amount of the policy and comments on the amount of the policy and comments of the comments of the amount of the policy and comments. The form and or supplement for relationing the bustoner, should be send to the Chair Information Office. U.S. Paper Intelled 20 Commence, P.O. Box 1450, Alexandra, VA. 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commensioner for Patents, P.O. Box 1450, Alexandra, VA. 2213-1450.

Substitu	ite for form 1449A/PT0)			Complete if Known		
				Application Number	10/788,426		
INF	DRMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
STA	TEMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625		
	(Use as many sh	eets as	necessary)	Examiner Name	Heidi L. Reese		
Sheet	eet 17 of 37		Attorney Docket Number	BAYER-0044			

C C C C C	0127 0128 0129 0130 0131 0132 0133	Foreign Patent Document Country Code* - Number* - Nind Code* (if Anown) WC-02/44156 WC-02/44156 WC-02/55091 WC-02/55091 WC-02/5509102 WC-02/550900 WC-02/550900	Publication Date MM-DD-YYYY 06-06-2002 06-06-2002 08-01-2002 08-01-2002 08-01-2002	Name of Patentee or Applicant of Cited Document Giaxo Group Limited et al. Pitzer Products Inc. et al. Giaxo Group Limited et al. Padia et al. Aventis Pharma S.A. et al.	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
c c c c c c c c c	0128 0129 0130 0131 0132	WO-02/44158 WO-02/50091 WO-02/559931 WO-02/059102 WO-02/059000	08-06-2002 08-27-2002 08-01-2002 08-01-2002	Limited et al. Pfizer Products Inc. et al. Glaxo Group Limited et al. Padia et al. Aventis Pharma		
C C C	0129 0130 0131 0132 0133	WO-02/55091 WO-02/55981 WO-02/559102 WO-02/669900	08-27-2002 08-01-2002 08-01-2002	Inc. et al. Glaxo Group Limited et al. Padia et al. Aventis Pharma		
C C C	2130 2131 2132 2133	WC-02/059081 WC-02/059102 WC-02/060900	08-01-2002 08-01-2002	Limited et al. Padia et al. Aventis Pharma		
C C	2131 2132 2133	WO-02/059102 WO-02/060900	08-01-2002	Aventis Pharma		
c c	C132	WO-02/060900				
C	2133		08-08-2002			abs
c-		WO-02/062763		Telik, Inc. et al.		
	2134		08-15-2002	Bayer Corporation et al.		
C		WO-02/070008	09-12-2002	Imclone Systems Incorporated et al		
	2135	WO-02/076930	10-03-2002	Telik, Inc.		
C	2136	WO-02/076977	10-03-2002	Bayer Corporation et al.		
C.	2137	WO-02/083628	10-24-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
c	2138	WO-02/083642	10-24-2002	Boshringer Ingelheim Pharmaceuticals, Inc.		
c	2139	WO-02/085857	10-31-2002	Bayer Corporation et al.		
c	2140	WO-02/085859	10-31-2002	Bayer Corporation et al.		
С	2141	WO-02/088090	11-07-2002	Vertex Pharmaceuticals Incorporated et al.		
С	C142	WO-02/092576	11-21-2002	Boehringer Ingelheim Pharmaceuticals, Inc.		
c	C143	WO-03/004523	01-16-2003	Bayer Aktiengelischaft et al.		
c	2144	WO-03/005999	01-23-2003	Boehringer Ingelheim Pharmaceuticals, Inc.		
С	C145	WO-03/047523	06-12-2003	Onyx Pharmaceuticals, Inc.		
C	2146	WC-03/047579	06-12-2003	Bayer Corporation et al.		

Date Examiner 07/13/2011 /Heidi Reese/ Considered Signature

"EXAMPLE 16(bit if reference considered, whether or not citation is in conformance with MEPF 600. Draw line through citation if not in conformance and not considered with a conformance of the conformation o Alexandria, VA 22313-1450.

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwo	IK HBOU	ction Act of 1995, no persons an	e required to respond to a collection of it	normation unless it contains a valid UMB control number
Substitute	for form 1449A/PTC)			Complete if Known
				Application Number	10/788,426
	NFORMATION DISCLOSURE TATEMENT BY APPLICANT Filing Date March 1, 2004 First Named Inventor Jacques Dumas	March 1, 2004			
STAT	LEMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas
				Art Unit	1625
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
Sheet	18	of	37	Attorney Docket Number	BAYER-0044

SHeet	10	OI OI	37	Allomey Docr		DAT	EN-0044	
			FOREIGN PA	ATENT DOC	UMENTS			
Examiner Initials*	Cite No.1	Foreign Patent	Document Number ⁴ - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Pat Applicant o Docum	of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	C147	١	VO-03/056036	07-10-2003	Catalyst Bio Limited et al			
	C148	,	VO-03/059373	07-24-2003	Ramot at Te University Lt al			
	C149	1	VO-03/060111	07-24-2003	Catalyst Bio Limited et al			
	C150	١	VO-03/065995	08-14-2003	Supergen, li al.			
	C151	١	VO-03/068223	08-21-2003	Bayer Corpo et al			
	C152	١	VO-03/068228	08-21-2003	Bayer Corpo et al.			
	C153	١	VO-03/068229	08-21-2003	Bayer Corpo et al			
	C154	١	VO-03/068746	08-21-2003	Bayer Corpo et al.			
	C155	١	VO-03/082272	10-09-2003	Chiron Corp et al			
	C156	١	VO-03/094626	11-20-2003	KMB Produk AG et al.	ktions		abs
	C156a	١	VO-03/097854	11-27-2003	Sugen, Inc.	et al.		
	C157	,	VO-03/099771	12-04-2003	Novartis AG	et al.		
	C158	W	O-2004/004720	01-15-2004	Astex Techr Limited et al			
	C159	W	O-2004/019941	03-11-2004	MERCK PA GMBH et al			
	C160	W	O-2004/037789	05-06-2004	MERCK PA GMBH et al.			
	C161	w	O-2004/043374	05-27-2004	Dana-Farbe Cancer Insti- Inc. et al.	tute		
	C162	W	O-2004/045578	06-03-2004	NOVARTIS al			
	C163	W	O-2004/052880	08-24-2004	ASTRAZEN AB et al.	ECA		
	C164	w	O-2004/078128	09-16-2004	Bayer Pharmaceut Corporation			
	C165	w	O-2004/078748	09-16-2004	Bayer Pharmaceut Corporation			
	C166	W	O-2004/078747	09-16-2004	Bayer Pharmaceuticals Corporation et al.			
	C167	W	O-2004/078748	09-16-2004	Bayer Pharmaceut Comeration			
Examiner		/Unidi Do	200/	Date			07/13/2011	

/Heidi Reese/ Signature Considered

Consideration of the Considera Alexandria. VA 22313-1450

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Under the Paperwo	IIK HBOU	ction Act of 1990, no persons ar	e required to respond to a corection of	mormation unless it contains a valid UMB control number		
Substit	ute for form 1449A/PT0)			Complete if Known		
				Application Number	10/788,426		
	ORMATION			Filing Date	March 1, 2004		
STA	ATEMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625		
	(Use as many she	eets as	necessary)	Examiner Name	Heidi L. Reese		
Choot	10	of	37	Atternov Deaket Mumber	BAVED-0044		

		FOREIGN PA	ATENT DOCL	IMENTS			
Examiner	Cite	Foreign Patent Document	Publication	Name of Pate Applicant of	ntee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Document		Passages or Relevant Figures Appear	T ⁶
	C168	WO-2004/085399	10-07-2004	MERCK PATI GMBH et al	ENT		
	C169	WO-2004/085425	10-07-2004	AMGEN INC.			
	C170	WO-2004/108713	12-16-2004	Warner-Lamb Company LLC al.			
	C171	WO-2004/108715	12-16-2004	Warner-Lamb Company LLC al.			
	C172	WO-2004/113274	12-29-2004	Bayer Pharmaceutic Corporation e			
	C173	WO-2005/000284	01-06-2005	Bayer Pharmaceutic Corporation e			
	C174	WO-2005/002673	01-13-2005	Astex Techno Limited et al.			
	C175	WO-2005/004863	01-20-2005	MERCK PAT GMBH et al.			
	C176	WO-2005/004864	01-20-2005	MERCK PATI GM8H et al	ENT		l
	C177	WO-2005/005389	01-20-2005	MERCK PATE GMBH et al.	ENT		
	C178	WO-2005/005434	01-20-2005	NOVARTIS A al.	G et		
	C179	WO-2005/009367	02-03-2005	AMBIT BIOSCIENCE CORPORATION			
	C180	WO-2005/009961	02-03-2005	Bayer Pharmaceutic Corporation e			
	C181	WO-2005/011700	02-10-2005	SMITHKLINE BEECHAM CORPORATION	ON et		
	C182	WO-2005/018252	02-24-2005	Ariad Gene Therapeutics, et al.			
	C183	WO-2005/019192	03-03-2005	MERCK PATE GMBH et al	ENT		abs
	C184	WO-2005/032548	04-14-2005	CHIRON CORPORATION al.	ON et		
	C185	WO-2005/037273	04-28-2005	CHIRON CORPORATION al.	ON et		
	C186	WO-2005/037285	04-28-2005	CHIRON CORPORATION	ON et		
Examiner Signature		/Heidi Reese/	Date Consid	dered	07/13	/2011	

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered "EXAMINES! Initial if selevenes considend, whether or not distion is in conformance with MEPE DD Dark line through clatter in a conformance and not considered include cogol with one time with next communication to applicant." Please indirect control of the policy of the common selection designation representations of the common selection of

Alexandria VA 22313-1450

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

_		Under the Paperwo	к неси	zion act or 1995, no persons an	e required to respond to a collection of it	mormation unless it contains a valid UMB control number		
	Substitute	for form 1449A/PTC)		Complete if Known			
					Application Number	10/788,426		
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004		
:	STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas		
					Art Unit	1625		
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
<u>_</u> 5	Sheet	20	of	37	Attorney Docket Number	BAYER-0044		

		Foreign Patent Document			Pages, Columns, Lines.	
Examiner Initials*	Cite No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
	C187	WO-2005/037829	04-28-2005	MERCK PATENT GMBH et al		abs
	C188	WO-2005/042520	95-12-2005	MERCK PATENT GMBH et al.		abs
	C189	WO-2005/047283	05-26-2005	MERCK PATENT GMBH et al.		abs
	C190	WO-2005/048948	06-02-2005	Ambit Biosciences Corporation et al.		
	C191	WO-2005/049803	06-02-2005	MERCK PATENT GMBH et al.		abs
	C191a	WO-2005/056764	08-23-2005	Compound Therapeutics, Inc. et al.		
	C192	WO-2005/058832	06-30-2005	MERCK PATENT GMBH et al		
	C192a	WC-2005/059179	06-30-2005	Bayer Pharmaceutical Corporation et al.		
	C193	WO-2005/075425	08-18-2005	MERCK PATENT GMBH et al.		
	C194	WO-2005/089443	09-29-2005	The Penn State Research Foundation et al.		
	C195	WO-2005/110994	11-24-2005	Bayer Pharmaceuticals Corporation et al.		
	C196	WO-2006/026500	03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C197	WC-2006/026501	03-09-2006	Bayer Pharmaceuticals Corporation et al.		
	C198	WO-2006/027346	03-16-2006	ALTANA PHARMA AG et al.		
	C199	WO-2008/034797	04-06-2006	BAYER HEALTHCARE AG et al.		
	C200	WO-2006/094828	09-14-2006	BAYER HEALTHCARE AG et al.		
	C201	WO-2006/105844	10-12-2006	MERCK PATENT GMBH et al		abs
	C202	WO-2006/125540	11-30-2006	BAYER HEALTHCARE AG et al		
	C203	WC-2007/015947	02-08-2007	BAYER HEALTHCARE LLC et al.		
	C204	WO-2007/039403	04-12-2007	ALTANA PHARMA		

Signature

Exclusion Indigent and a finded and a second considered, whether or not define in a continuous with MEPS dots. Draw line in rough indigent in an in a continuous and not a considered with the continuous and indigent in the continuous and not a considered with the continuous and indigent in the continuous and indigent in the continuous and indigent indigent in the continuous and indigent indigent in the continuous and indigent indignormal indigent indigent indigent indigent indigent indigent ind Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /H.R./

PTO/SB/08a (11-07)

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Linday the Danasanik Back often Act of 1006, no persons to respond to a collection of information unless it contains a valid OMB control number

	_	CIND TO TOPOTHO	III I IDUU	Journal of 1000, no poroons of	o roquiros to rooporta to a concentrar or	I TOTAL OF THE TOTAL TOTAL TO A VALID ON TO CONSTRUCT ON THE TOTAL
1	Substitute	for form 1449A/PTC)			Complete if Known
					Application Number	10/788,426
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004
	STAT	LEMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas
					Art Unit	1625
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
₹	Sheet	21	of	37	Attorney Docket Number	BAYER-0044

Sheet	21		of	37	Attorn	ey Docke	t Number	BAY	ER-0044	
				FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1			Document		lication Date	Name of Pate Applicant of	Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	
minus	110.	Country (Code* - N	Number ⁴ - Kind Code ⁵ (if known)	MM-D	D-YYYY	Docume		Figures Appear	T ⁶
	C205		W	O-2007/039404	04-1	2-2007	ALTANA PH. AG et al.	ARMA		l
	C205a		W	O-2007/047955	04-2	6-2007	BAYER HEALTHCAF LLC et al.	RE		
	C206		W	O-2007/053573	05-1	0-2007	Bayer Pharmaceuti Corporation			
	C207		W	O-2007/054215	05-1	8-2007	BAYER HEALTHCAR et al.	RE AG		
	C207a		W	O-2007/056011	05-1	8-2007	BAYER HEALTHCAF LLC et al.	RE		
	C207b		W	O-2007/056012	05-1	8-2007	BAYER HEALTHCAF LLC et al.	RE		
	C208		w	O 2007/059094	05-2	4-2007	Bayer Pharmaceuti Corporation			
	C209		w	D-2007/059154	05-2	4-2007	Pharmaceuti Corporation			
	C210		W	O-2007/059155	05-2	4-2007	Bayer Pharmaceuti Corporation			
	C211		W	O-2007/064872	06-0	7-2007	Bayer Pharmaceuti Corporation			
	C215		W	O-2007/123722	11-0	1-2007	Bayer Pharmaceuti Corporation			
	C216		W	O-2007/139930	12-0	6-2007	Bayer Pharmaceuti Corporation			
	C218		W	O-2008/079968	07-0	3-2008	Bayer Pharmaceuti Corporation			
	C219		W	0-2008/079972	07-0	3-2008	Bayer Pharmaceuti Corporation :			
	C220		W	O-2008/089389	07-2	4-2008	Bayer Pharmaceuti Corporation	cals		
	D1			EP-0016371	10-0	1-1980	F. Hoffman-L Roche & Co. Aktiengesells			abs
Examiner			/He	idi Reese/		Date Consid	lered	07	13/2011	

Signature

Considered

EVALUATION Table If retermore considered, whether or not callion in in conference with MEPF (00) Date line through distaint in an accordance and not considered with MEPF (00) Date line through distaint in an accordance and not considered with the conference of the Alexandria, VA 22313-1450.

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE opulied to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449A/PTO Complete if Known 10/788 426 Application Number INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 22 of 37 BAYER-0044 Attorney Docket Number

Cileer	22	0.	1 97		ey Ducke		DATE	LI 1-0044	
			FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Pater Country Code ²	nt Document Number ⁴ - Kind Code ⁵ (<i>if known</i>)		lication Date D-YYYY	Name of P Applicant Docu	t of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	D2		EP-0107214	05-0	2-1984	Duphar Internation Research I			
	D3		EP-0116932	08-2	9-1984	BASF Aktiengese	elischaft		abs
	D3a		EP-0192263	07-2	9-1992	Ishihara Sa Kaisha Ltd	. et al.		
	D4		EP-0192263	08-2	7-1986	Ishihara Sa Kaisha Ltd			
	D5		EP-0202538	11-2	6-1986	Bayer AG			abs
	D6		EP-0230400	07-2	9-1987	CIBA-GEIC	BY AG		abs
	D6a		EP-0233559	08-2	6-1987	Ishihara Sa Kaisha Ltd	. et al.		
	D7		EP-0233559	05-0	6-1992	Ishihara Sa Kaisha Ltd	angyo . et al.		
	D8		EP-0242666	10-2	8-1987	BASF Aktiengese			abs
	D9		EP-0264904		7-1988	Ishihara Sa Kaisha Ltd	. et al.		
	D10		EP-0314615	05-0	3-1989	Ciba-Geigy	/ AG		abs
	D11		EP-0335158	10-0	4-1989	Bayer AG			abs
	D12		EP-0359148		1-1990	Ishihara Sa Kaisha, Lto			
	D13		EP-0371876	06-0	6-1990	Novapham	ne		abs
	D14		EP-0379915	08-0	1-1990	Bayer AG			abs
	D15		EP-0380048	08-0	1-1990	Ishihara Sa Kaisha Lto			
	D16		EP-0381987	08-1	6-1990	Ishihara Sa Kaisha, Lto	i. et al.		
	D17		EP-0405233		2-1991	Mitsubishi Corporation			
	D18		EP-0425443		2-1991	Ciba-Geigy			abs
	D19		EP-0459887	12-0	4-1991	Novapham			abs
	D20		EP-0502504	09-0	9-1992	Matsushita Industrial C	Co., Ltd.	_	
	D21		EP-0509795	10-2	1-1992	American I Products Corporation			
	D22		EP-0676395		1-1995	Hoechst Aktiengese			abs
	D23		EP-0690344	01-0	3-1996	Konica Con			
	D24		EP-0709220	05-0	1-1996	Canon Kat Kasha	oushiki		
Examiner Signature		/Heidi F	leese/		Date Consid	ered		07/13/2011	

EXAMINE: Table 1 interprise considered, whether or not dathor in a notiferance with IMEPS 000 from time through addors if not in continuous and not considered includes copy of this form with and commissionable to applicate. Application stages actioned designation market of protocol "See fortification for the Continuous assessment of the Continuous and Section 1 in the Sec

This collection of information is negatived by 37 CFR 137 and 1.98. The information is registed to obtain or retain a bound by the public which is to life (and by the USP*10.0 process) an expectation. Confidentially is good process of the public or the collection is entertained to the bit 2 bound to recommend, unduring granting preparing propering and process of the collection is entertained to the bit 2 bound to recommend, unduring granting preparing to the collection of the

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 10/788 426 INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 23 of 37 BAYER-0044 Attorney Docket Number

		FOREIGN PA		1	Pages, Columns, Lines.	
Examiner Initials*	Cite No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Т6
	D24s	EP-0709225	05-01-1996	Nippon Paper Industries Co., Ltd.		
	D25	EP-0709225	08-05-1998	Nippon Paper Industries Co., Ltd.		
	D26	EP-0860433	08-26-1998	Kırın Beer Kabushiki Kaisna		
	D27	EP-1056725	12-06-2000	Bayer Corporation		
	D28	EP-1199306	04-24-2002	Banyu Pharmaceutical Co., Ltd		
	D29	EP-1256587	11-13-2002	The Kitasato Institute		
	D30	EP-1537075	08-08-2005	Neurosearch A/S et al.		
	E1	CH-479557	11-28-1969	Dr. A Wander AG		abs
	F1	CL-38688	06-04-1993	Ciba-Geigy AG		
	G1	CA-2 146 707	10-12-1995	Hoechst Aktiengesellschaft		
	G2	CA-2,028.536	04-28-1991	Ciba-Geigy AG		
	H1	DD-253997	02-10-1988	Karl-Marx- Universität, Büro Für Neuerungen und Schutzrechte		abs
	н	DE-487014	11-14-1929	I.G. Farbenindustrie Akt -Ges		
	12	DE-511468	10-16-1930	I.G. Farbenindustrie Akt -Ges		abs
	13	DE-523437	04-02-1931	I.G Farbenindustrie Akt -Ges		
	14	DE-2436179	04-10-1986	Shionogi & Co. Ltd.		abs
	15	DT-2501648	07-24-1975	The Dow Chemical Co		abs
	16	DT-2436179	02-06-1975	Shionogi & Co., Ltd.		abs
	17	DE-3305868	08-23-1984	BASF AG		abs
	18	DE-3529247	11-20-1986	Bayer AG		abs
	19	DE-3540377	05-21-1987	Bayer AG		abs
	J1	FR-1.457.172	09-19-1966	Ferrania S.p.A.		abs
	K1	GB-771,333	03-27-1957	J R. Geigy AG.		
	K2	GB-828.231	02-17-1960	J.B. Geigy AG		

Signature EXAMENT: Initial if reference considered, whether or not citation is in conformance with MPEP 000 Draw line through distion if not in conformance and not considered include copy of the form with real communication to applicant. **Applicant** is using existent designation number (optional)** See Need Code's of USPTO Patert Documents at year of the regin of the Engineen Impute Communication in the Communication of the Communica

Considered

into consolar of infloration is required by an or 11 for an in the infloration of the required to down or teams at version is required by a consolar of the property of the pack which is not because of the property of the pack which is not because of the property of the pack which is not because of the property of the pack which is not because of the property of the pack which is not because of the property of the pack which is not because of the property of the pack which is not property of the pack which is no Sex 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		Under the Paperwo	rk Redu	ction Act of 1995, no persons are	e required to respond to a collection of it	nformation unless it contains a valid OMB control number
1	Substitute	for form 1449A/PTC)			Complete if Known
L					Application Number	10/788,426
L				CLOSURE	Filing Date	March 1, 2004
L	STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas
L					Art Unit	1625
L		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
1	Sheet	24	of	37	Attorney Docket Number	BAYER-0044

		FOREIGN PA	ATENT	DOCU	MENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ⁵ (if known)		lication Date D-YYYY	Applica	Patentee or ant of Cited cument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	КЗ	GB-921,682	03-2	0-1963	J.R. Geig	y AG.		
	K4	GB-1,110,099	04-1	8-1968	Rhone- F S.A.	oulenc		
	K4a	GB-1 111,554	05-0	1-1968	Societa l Ferrania	Per Azioni		
	К5	GB-1 590 870	06-1	0-1981	Shlonogi Kabushil			
	L1	HU-P0004437	08-2	8-2001	Bayer Co	orporation		abs
	M1	IR-26555	01-1	3-2000	Bayer Co	orporation		abs
	N1	JP-44-2569	02-0	3-1969	Sankyo (and Asal Ind. Co	ni Chem. Ltd		abs
	N2	JP-50-76072	06-2	1-1975	Shionogi KK	-		abs
	N3	JP-50-77375	06-2	4-1975	Shionogi KK	Seiyaku		abs
	N4	JP-50-149668	11-2	9-1975	unknown	1		abs
	N5	JP-51-63170	06-0	1-1976	Shionogi Shinzabi			abs
	N6	JP-51-80882	07-1	5-1976	Shionogi KK	Seiyaku		abs
	N7	JP-53-86033	07-2	9-1978	Shionogi	Co Ltd.		abs
	N8	JP-54-32468	09-0	3-1979	Otsuka Pharmad Ltd.	eutical Co		abs
	Na	JP-55-98152	07-2	5-1980	HOKKO IND. CO	CHEM.		abs
	N10	JP-55-124763	09-2	6-1980	Ishihara Chemica			abs
	N11	JP-55-162772	12-1	8-1980	Shionogi	& Co. Ltd.		abs
	N13	JP-57-53785	11-1	5-1982	Shionogi KK	,		abs
	N14	JP-58-21826	05-0	2-1983	Shionogi KK			abs
	N16	JP-61-20039	01-2	8-1986	Konishiro Ind. Co.,	oku Photo Ltd.		abs
	N15	JP-63-214752	09-0	7-1988	Fuji Phot Ltd.	o Film Co.		abs
	N17	JP-64-9455	01-1	2-1989	Fuji Phot Co., Ltd.	o Film		abs
	N18	JP-1-102461	04-2	0-1989	Konica C	orp.		abs
	N19	JP-1-132580	05-2	5-1989	Ciba Gei	gy AG		abs
	N20	JP-1-200254	08-1	1-1989	Konica C	orp		abs
Examiner Signature		/Heidi Reese/		Date Consid	ered	07/	13/2011	

Considered

FANNER in fails if reference considered, whether or not clastion is in conformance with MFPE 600 Dave like though citation if in or not considered include cycy of this form with not communication to applicant. Applicant's unique citation designation number (colorisal) "See Refind Codes of USF) P Paint Documents and communication to applicant." Applicant's unique citation designation number (colorisal) "See Refind Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered to Codes of USF) P Paint Discovered to Codes of USF) P Paint Discovered to Paint Discovered

Substitute for form 1449A/PTO

N33

T-13

LB-6124

CL-38689

DE-523437

PTO/SB/08a (11-07)

abs

Complete if Known

10/788 426

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number Application Number

INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 25 of 37 Attorney Docket Number BAYER-0044 FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages Columns Lines Name of Patentee or Examine Where Relevant Applicant of Cited Initials* No Date Passages or Relevant Country Code³ - Number⁴ - Kind Code⁵ (if kn Docum MM-DD-YYYY Figures Appear N21 JP-1-259360 10-17-1989 Kenica Corp. N22 JP-2-22650 01-25-1990 Konica Corp. Mos JP-2-23337 01-25-1000 Konica Corp. ahs N24 JP-2-35450 Konica Corp. Nos JP-2-105146 04-17-1990 Konica Corp. Konica Corp. abs N27 JP-2-150840 06-11-1990 Konica Corp. ahe Fuli Photo Film Co N28 JP-3-53247 03-07-1991 abs JP-3-144634 06-20-1991 N29 Konica Corp. abs Fuli Photo Film Co. Nan JP-3-198049 08-29-1991 abs Fuji Photo Film Co. JP-6-75172 09-21-1994 abs Ltd. Green Cross Corp. N32 JP-8-301841 11-10-1006 aho et al. Mitsubishi JP-10-306078

04-02-1931

11-17-1998

01-12-2000

06-04-1993

Chemical Corp.

Ciha-Geigy AG

Bayer Corporation

I.G. Farbenindustrie Akt -Ges

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volum No.				
	P7	Avruch et al., "Raf meets Ras. completing the framework of a signal transduction pathway," TIBS 19; July 1994, pp. 279-283			
	P9a	Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," Expert Opinion Therapeutic Targets, 2006, Vol. 10, No.6, pp. 967-876			
	P10	Balam et al., "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: Burger's Medicinal Chemistry and Drug Discovery, 5 th ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1,pp. 949-982			
	P17	Berge et al. "Pharmaceutical Salts." Journal of Pharmaceutical Sciences. January 1977:1-19 Vol. 66, No. 1			

Examiner /Heidi Reese/ Date 07/13/2011 Signature Considered "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include your of this form with earl communication to nonlicent. Applicant's unique citation despination number (optional). See Kinds Codes of USPTO Patent Documents at

"EAA/INE!! Intell if reference considend, whether on not dathon is in continuous with MEP 90.00 bark limit brough addoor if not in continuous and not considered include copy of the form with real communication to applicant." Replace it usuage calculate designation nature following: "See refined colored USFTO Parties Documents at include copy of the property of the property of the parties obscured." What of the parties of the parties obscured. "Not of document by the appropriate symbols as indicated on the document under WPO Standard ST 1 of the possible." Application is object as check make there of English palargae Transitions is attained.

This collection of information is required by 37 CFR 137 and 138. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO) to proceed in application of Confederation's promotive, including pathway. process) an appreciant obtainment of Superior Section (Section 1) and Section 1) and Section (Section 1) and Section 1) Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons

PTO/SB/08a (11-07)

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTC)			Complete if Known
				Application Number	10/788,426
				Filing Date	March 1, 2004
Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	PPLICANT	First Named Inventor	Jacques Dumas		
				Art Unit	1625
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
Shoot	26	of	37	Attornov Dooket Number	BAVED-0044

		NON PATENT LITERA	TURE DOCUMENTS	3						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, s number(s), publisher, c	ymposium, catalo	g, etc.), date, page(s), volume-issue	T ²					
	P22	Martin-Blanco, *p38 MAPK signalling cascades, a 2000	ncient roles and nev	r functions," BioEssays, 22:637-645,						
	P23	Foussard-Blanpin, Odette, "Comparative pharmac nervous system," Ann. Pharm. Fr. (1982), 40 (4),		ostituted carboxamides upon central						
	P25	Bollag et al., "Raf pathway inhibitors in oncology." 1436-1441.	Current Opinion in I	nvestigational Drugs (2003) 4(12). pp.						
	P26	Botton et al., "Chapter 17. Ras Oncogene Directe Medicinal Chemistry, Vol. 29. 1994, pp. 165-174	d Approaches in Ca	noer Chemotherapy," Annual Reports In						
	P28a	Boyer, S.J., "Small Molecule Inhibitors of KDR (VI Relationships," Current Topics in Medicinal Chem								
	P50	Copéret et al., 'A Simple And Efficient Method for Elsevier Science Ltd., Pergamon Press, Oxford, U								
P53a Crump, Micheal, "Inhibition of ral kinase in the treatment of acute myeloid feukemas," Medline Abstra- ISSN.1381-6128, Current Pharmaceutical Design, Vol. 8, Issue 25, 2002, pp. 2243-2248										
	P57	Daum et al "The ins and outs of Raf kinases," TI	BS 19, November 19	94, pp. 474-490						
	P66	Dumas, J. *Protein kinase inhibitors from the urea class,* Curr. Opin. in Drug Discovery and Dev., 5(s):718-727, 2002								
	P67	Dumas et al., "Discovery of a New Class of p38 Kinase Inhibitors," Bioorganic & Medicinal Chemistry Letters Vol. 10, (2000), pp. 2047-2050								
	P68	Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Poten: Chemistry Letters, 2000, Vol. 10, pp. 2051-2054	t and Selective p38 h	Kinase Inhibitors," Bioorganic & Medicinal						
	P68a	Dumas, J., "Growth factor receptor kinase inhibito Drug Discovery & Development, 2001, Vol. 4, No.		and clinical impact," Current Opinion in						
	P68b	Dumas, J., 'Protein kinase inhibitors: emerging ph Patents (2001) Vol. 11, No. 3, pp. 405-429	armacophores 1997	-2000," Expert Opinion on Therapeutic						
	P68c	Dumas et al., "Orally Active p38 Kinase Inhibitors Society National Meeting 2001, Med I 256, 1 page		,* Poster, 222nd American Cancer						
	P68d	Dumas, J., 'Raf Kinase Inhibitors,' Expert Opinior 1998	on Therapeutic Pat	lents, Vol. 8, No. 12, pp. 1749-1750,						
	P69	Dumas et al "Recent developments in the discov Opinion in Drug Discovery & Development, 2004,								
Examiner Signature		/Heidi Reese/	Date Considered	07/13/2011						

**CASIMERI Initial is reference considered, whether or not clation is in conformance with METE 60D Davis line through clation in rid in conformance with METE 60D Davis line through clation in rid in conformance with METE 60D Davis line through clation in rid in conformance with meteory of the form with next communication to applicant. 'Applicant's unspeciation designation number (cpictoral) 'See Redid Codes of USPTO Patent Documents at Warrings (1987) District of 1987 DI OH. 'Effect for line insured the colored to the ride of 1987 DI OH. 'Effect for line insured the colored to ride of 1987 DI OH. 'Effect for line insured the colored to ride of 1987 DI OH. 'Effect for line insured to the colored to ride of 1987 DI OH. 'Effect for line insured to ride of 1987 DI OH. 'Effect for line insured to ride of 1987 DI OH. 'Effect for line insured to obtain or retain about 1987 by packed which is to 1987 Get of 1987 and 1987 DI OH. 'Effect for line insured to obtain or retain about 1987 by packed which is to 1987 Get OH. Bus 1997 OH. 'Effect for line insured to obtain or retain a benefit by the packed which is to 1987 Get OH. Bus 1997 OH. 'Effect for line insured to obtain or retain a benefit by the packed which is to 1987 Get OH. Bus 1997 OH. 'Effect for line insured to obtain or retain a benefit by the packed which is to 1987 Get OH. 'Effect for line insured to obtain or retain a benefit by the packed which is to 1987 Get OH. 'Effect for line insured to obtain or retain a benefit by the packed with a benefit by the packed of 1987 Get OH. 'Effect for line insured by the benefit by the packed of 1987 Get OH. 'Effect for line insured by the packed of 1987 Get OH. 'Effect for line insured by the benefit by the packed of 1987 Get OH. 'Effect for line insured by the benefit by the packed of 1987 Get OH. 'Effect for line insured by the packed of 1987 Get OH. 'Effect for line insured by the packed of 1987 Get OH. 'Effect for line insured by the packed of 1987 Get OH. 'Effect for line insured by the packed of 1987 Get OH. 'Effect

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /H.R./

PTO/SB/08a (11-07) Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1	449A/PTO			Complete if Known			
				Application Number	10/788,426			
INFO	RMA	TION DISCLO	SURE	Filing Date	March 1, 2004			
STAT	ГЕМЕ	NT BY APPLI	CANT	First Named Inventor	Jacques Dumas			
				Art Unit	1625			
	(Use as	many sheets as necessa	ry)	Examiner Name	Heidi L. Reese			
Sheet	27	of 37		Attorney Docket Number	BAYER-0044			
			NON PATENT	LITERATURE DOCUMENTS				
Examiner nitials *	Cite No.1	the item (book, mag	azine, journal, s		article (when appropriate), title of stc.), date, page(s), volume-issue ere published.	T2		
	P22	Martin-Blanco, 'p38 MAPK signalling cascades' ancient roles and new functions,' BioEssays, 22.637-645, 2000						
	P70	Durnas et al., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor." Bioorganie & Medicinal Chemistry Letters, 2002, Vol. 12, pp. 1559-1562						
	P107	Gura, "Systems for identifying new drugs are often faulty." Science, 1997, Vol. 278, (5840), pp. 1041-1042, MEDLINE with Full text						
Kubo et al., "Synthesis and structure-activity relation P147 VEGF receptor tyrosine kinase selective inhibitors." 2002, Vol. 43. p. 182, abstract no. 913				vity relationship of quinazoline-u nhibitors.` Proceedings of the A	rea derivatives as novel orally active merican Association of Cancer Res			
	P149	Kumar et al., "Drugs ta	rgeted against prot	ein kinases" Expert Opin. Emer	ging Drugs 6(2):303-315 (2001)			
	P166	Lyons et al., 'Discovery	of a novel Raf kin	ase inhibitor," Endocrine-Relate	d Gancer, 2001, Vol. 8, pp. 219-225			
	P224	Regan et al., "Pyrazole Candidate," J. Med. Ch		itors of p38 MAP kinase: From L i, 2002	ead Compound to Clinical			
	P248		ad by a Combinato	eas as a New Class of Raf Kina rial Chemistry Approach," Broor	use Inhibitors: Identification of a ganic & Medicinal Chemistry Letters,			
	P249	Smith et al., (Abstract) Topics in Medicinal Ch			ent of RAF Kinase Inhibitors," Current			
	P276	Thaimattam et al., '3D- confirmation with struct	QSAR CoMFA, Co ure-based studies	MSIA studies on substituted ure " Bioorganic & Medicinal Chem	eas as Raf-1 kinase inhibitors and its listry, 2004, Vol. 12, pp. 6415-6425			
	P278	Thompson et al., 'Rece discovery," Curr. Opin	ent progress in targ Pharmacol., Augu	eting the Rat/MEK/ERK pathwa st 2005 Vol. 5, Number 4, pp. 3	y with inhibitors in cancer drug 50-356			
	P294	Chemistry & Biology, 1	997. Vol. 4, Numb	-11				
	P312		Tyrosine Kinase S	elective Inhibitors," Proceedings	Urea Derivatives as Novel Orally s of the American Association of			

Considered "EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered

Abstract of DE 3305866 A1, August 23, 1984, BASE AG et al

/Heidi Reese/

P313

P315

Examiner

Active VCCI resolution (1) delite inclease Secretary in Indiana (1) and (1) an Proceedings of the American Association for Cancer Research, Vol. 42, March 2001 (2001-03), page 923,

92nd Annual Meeting of the American Association for Cancer Research: New Orleans, LA, USA: March 24:28,

Date

07/13/2011

"EXAMINE. In itside if reference considend, whether or not dation is in conformance with MEPE DD. Dark limit insight a claim if not in conformance and not considered include cogol with our point with next communication to applicate." Replicated suspens detailed designation national regional. See finded code of USET DP Benefit becomes at including the common of the property of the part of the Empore must procede the sensit number of the patient document." Find of document by the appropriate symbols as indicated on the document. The collection of information is required by 20° CPR 10° and 118°. The information is required to data or retain a benefit by the patient which is to fit (part by the CPR 10° CP Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are a

PTO/SB/08a (11-07)

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

to respond to a collection of information unless it contains a valid OMB control number

1	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Ū	Sheet	28	of	37	Attorney Docket Number	BAYER-0044	

			,		_
		NON PATENT LITERAT	URE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LE the item (book, magazine, journal, serial, sy number(s), publisher, cit	mposium, catalog	etc.), date, page(s), volume-issue	T²
	P316	Abstract of EP 4931 A (Equivalent 4,240,820), Ba	yer AG, 1 page	1980	
	P317	Abstract of EP 16371 (1980), 1 page, Hottmann-La	Roche AG		
	P318	Abstract of EP 16371, October 1, 1980, 1 page			
	P319	Abstract of EP 116932, August 29, 1984, 2 pages.			
	P320	Abstract of EP 116932, (1984), 2 pages, BASF AG	i		
	P321 Abstract of EP 0202538, (1986), 3 pages				
	P322	Abstract of EP 0202538 A1, "Growth Promoting Ag	ents, November 26,	1986, 4 pages, Bayer AG	
	P323	Abstract of EP 0405233A1, Mitsubishi Kasei Corp	., 2 pages 19	91	
	P324	Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1	page 199	1	
	P325	Abstract of EP 0676395A2, (1995), 3 pages, Hoeci	hst AG		
	P326	Abstract of EP 676395, (U.S. equivalent 5,698,581). December 16, 199	7. 1 page	
	P327	Patent Abstracts of Japan 02-022650, 01-25-1990,	2 pages, Konica Co	rp	
	P328	esp@cenet Abstracts of Japan 02-022650, 01-25-	1990, 1 page		
	P329	Patent Abstracts of Japan 02-023337, 01-25-1990	2 pages Konica Co	rp	
	P329a	Patent Abstracts of Japan 63-214752, 09-07-1988, Co. Ltd.	2 pages, tamily mer	nber of JP 6-07512 B4, Fuji Photo Film	
Examiner Signature		/Heidi Reese/	Date Considered	07/13/2011	

Signature

EXPRIGITATION

CONSISTENT OF THE PROPERTY OF T Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons a

PTO/SB/08a (11-07)

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to respond to a collection of information unless it contains a valid OMB control number

	Substitute	for form 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
	INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
	STAT	EMENT B	YΑ	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
Ū	Sheet	29	of	37	Attorney Docket Number	BAYER-0044	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appr the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s number(s), publisher, city and/or country where published.		T ²
	P330	esp@cenet Abstract of Japan 02-023337, 1 page 1990		
	P331	Abstract of JP 55162772 A2. Preparation of Substituted Acetic Acid Derivatives, Shiongi & Co. 1980, 1 page	o., Ltd. December	
	P332	Esp@cenet Abstract of WO 9822103, 28 May 1998. Philip Hedge et al.		
	P332a	Abstract of WO 9822098 A2, QLT Phototherapeutics Inc. et al., 05-28-1998, 1 page		
	P333a	Abstract of WO 9822103 A1, Zeneca Limited, published 05-28-1998, 1 page		
	P333b	Abstract of WO 9852559 A1, Bayer Corp. et al., published 11-28-1998, 1 page		
	P333c	Abstract of WO 9852562 A1. Verkalik, MSE, et al., published 11-26-1998, 1 page		
	P333d	Abstract of WO 9900357 A1, Vertex Pharm. Inc., published 01-07-1999. 1 page		
	P333a	Abstract of WO 9600064 A1, Pharmada & Upjohn S.P.A. et al., published 01-07-1999, 1 page	э	
	P333f	Abstract of WO 9932098 A2, Janssen Pharm NV, published 07-01-1999, 1 page		
	P333g	Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page		
	P333h	Abstract of WO 9932148 A1. Beth Israel Deaconess Medical Center et al., pub. 07-01-1999,	1 page	
	P333i	Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page		
	P333j	Abstract of WO 9932455 A1. Bayer Corp., published 07-01-1999, 1 page		
Examiner Signature		/Heidi Reese/ Date Considered 07/13/20	011	

Signature "EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents a

"EXAMINE! Initial Federate considered, whether or not distion in a conformance with MTPE 200 Draw line through cubino if not a conformance and not considered include copy of the local marking and the conformal countries of the countries of the conformal countries of the countries of the conformal countries of the countries of the conformal countries of the coun

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Light to Proposed Part of the Proposed Pa

-	Substitute	for form 1449A/PTC)			Complete if Known
					Application Number	10/788,426
				CLOSURE	Filing Date	March 1, 2004
	STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Jacques Dumas
					Art Unit	1625
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese
	Choot	30	of	37	Attornov Dooket Number	BAVER-0044

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published Pagge Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al. published 07-01-1999, 1 page Caplus 72:79046, Abstract of CH 479557. "Tuberculostatic and cancerostatic polybasic ureas." Dr. A. Wander, Daga October 15, 1969, 6 pages Caplus 84:180049, Abstract JP 56029871, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July P335 10, 1981, 1 page Caplus 84.43857, Abstract JP 58021626, "Alkanoic acid derivatives containing a pyridine ring," Maeda, Ryozo P336 et al., May 2, 1983, 1 page Capius 86 72448, Abstract JP 57053785, "Pyridine derivatives," Maeda, Rivozo et al., November 15, 1982, 1 P337 page Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives," November 15, 1982, 1 P339 page, Chugai Pharmaceutical Co., Ltd. Caplus 113.106314, Abstract of JP 2022650, "Silver halide color photographic material containing a cyan P340 coupler of 2-ureido-phenol type to improve dve developability and remove leguo evan dve." Noboru Mizukura et al. January 25, 1990, 1 page Caplus 113:142130. Abstract of JP 2023337, "Silver halide photographic material containing phenolic cyan P341 coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page Caplus 127.34137f, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth P246 factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329 Caplus 131 58658k, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas," D247 Miller, Scott, et al. July 1, 1999, WO 99 32,436 Caplus 131:73849b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al , July 1, 1999, WO 99/32110 P352 'Beilstein number' Collection, 28 pp. (1997) P353 'Beilstein number' Collection, 4 pp. (1997). P354 Derwent World Patents Index Search on 20-26 (1997) P355 Dumas J. "CAS Substructure," May 6, 1997, pp. 1-29

Examiner | Considered | Date | Considered |

WPO Standed ST 16F possible. "Applicant is to place a check mark here is Egiph Insignage, Translation is altribed."

This collection of Information is required by 27G FH 97 and 18F. The Information is required by the Information is required by the Information is required by 18F or Information is required to be information in public which is to 18F (and by the USPTO to proceed an application. Confidentially in governed by 98 U.S. C 122 and 97 CFR 1.14. This collection is estimated to take 2 hours to comprise, including gathering preparing addustmiting the comprised application into the USPTO Time will vary depending upon the individual case have formation of the Information of User Inform

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, 1/13-08-007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application Number 10/788 426 INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 31 of 37 BAYER-0044 Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	P356	Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pp. 1-19	
	P357	Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3	
	P358	Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49	
	P359	Substructure Search, pp. 1-29. (1997)	
	P360	Wild, Hanno, "Substructure #1," search, pp. 1-150, 1996	
	P361	A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filling date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages	
	P362	A "Notice of References Cited" from the USPTO for U.S. application 09/063,399, filling date of 5/22/98, Patent 6187799 issued 2/13/2001, inhibition of Raf Kinase Activity Using Aryl Ureas. 1 page	
	P363	A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filling date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages	
	P364	A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filling date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page	
	P365	A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 12/10/1999 Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page	
	P366	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filling date of 12/27/99, Patent 7329670 issued 2/12/2008. Inhibition of Rat Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas.	
	P367	A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filling date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page	
	P368	A "Notice of References Cited" from the USPYO for U.S. application 09/773,604. filing date of 2/2/01, Publication No US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxysryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	
	P369	A "Notice of References Cited" from the USPTO for U.S. application 09/773,659, filling date of 2/2/01, Publication No.: US 2001-0911135 A1, Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Dipheryl Ursea Ns Raf Kinase inhibitors, 1 page	
	P370	A "Notice of References Cited" from the USPTO for U.S. application 09/773.672. filling date of 2/2/01, Publication No.: US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diobernd Unea	

Date Considered /Heidi Reese/ 07/13/2011 Signature

Examiner

EXPRINGENT (Initial II reference considered whether or not delibon is in conformance with MFF 800 Draw line through citation in rice of nononomical and not considered systems. In the conformance of the conformance with memory of the conformance with memory of the conformance with memory of the rice of the Alexandria, VA 22313-1450.

Approved for use through 11/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPA

Substitute for form 1449A/PTO Complete if Known 10/788 426 Application Number INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT Jacques Dumas First Named Inventor 1625 (Use as many sheets as necessary) Evaminer Name Heidi L. Reese of 37 Attorney Docket Numbe BAYER-0044

		NON PATENT LITERAT	URE DOCUMENTS	•			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
	P371	A "Notice of References Cited" from the USPTO for Publication No : US 2001-0011136-A1 , Publication Diphenyl Ureas as Raf Kinase Inhibitors, 1 page	U.S. application 09 Date: August 2, 20	7773,675. filing date of 2/2/01, 01, Omega-Carboxyaryl Substituted			
	P372	A "Notice of References Cited" from the USPTO for Inhibition Of p38 Kinase Using Aryl And Heteroaryl					
	P373	A "Notice of References Cited" from the USPTO for inhibition Of Raf Kinase Using Symmetrical And Ur					
	P374	A "Notice of References Cited" from the USPTO for of RAF kinase using quinolyl, isoquinolyl or pyridyl		/777,920, filling date of 2/7/01, inhibition			
	P375	A "Notice of References Cited" from the USPTO for Carboxyaryl Substituted Diphenyl Ureas As Raf Kir					
	P376	A "Notice of References Cited" from the USPTO for Omega-Carboxyaryl Substituted Diphenyl Ureas A:					
	P376a	Co-pending application Serial No. 09/453,014, filed December 10, 1999, Dumas et al.					
	P377	Abandoned application Serial No. 09/776,935 filed	orial No. 09/776,935 filed December 22, 1998, Dumas et al.				
	P378	Co-pending application Serial No. 09/776,936 filed December 22, 1993, Miller et al.					
	P379	Issued application Serial No. 09/889,227 filed July	12, 2000, Riedl et al	., issued as 7351834, 4/1/2008			
	P380	Co-pending application Senal No. 09/993,847 filed November 27, 2001, Riedl et al., published as 2003- 0181442, 39/25/2003					
	P381	Issued application Serial No. 10/060.396 filed February 1, 2002, Miller et al., patent 7517980, issued 4/14/2009, also published as 2004-0102636, 5/27/2004					
	P382	Issued application Serial No. 10/071,248 filed Febr 5/5/2009, also published as 2003-139605, 7/24/201		et al., patent 7528255, issued			
	P383	Abandoned application Serial No. 10/086,417 filed 6/5/2003	March 4, 2002, Ried	ll et al., published as 2003-0105091,			
	P384	Abandoned application Serial No. 10/125,369 tiled 11/6/2003	April 19, 2002, Dum	as et al., published as 2003-0207914,			
Examiner Signature		/Heidi Reese/	Date Considered	07/13/2011			

Signature Considered U/T/3/2/11

**EXAMER: Initial if reference considered, whether or not distin as in conformance with MFEP 200 Draw line through cattoon if not in conformance and not considered include copy of the form with the action considered include copy of the form with the action conformance and not considered include copy and in the conformance of the conformance and not conformance and not considered include copy and include copy and

The collection of information is equived by 37 CFF1. 137 and 1.88. The information is required to obtain or retain a breaft by the public which is to life (and by the LSFF) or and a state of the public which is to life (and by the LSFF) or and state of the local public which is to life (and by the LSFF) or and schmiding the completed application from the LSFFT of the way beyonding upon the middeduct across your comments on the incomment of time you are used to employ the comment of the local public way to be a state of t

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

_	U	nder trie Paperwol	IK Heau	zion act of 1995, no persons an	required to respond to a collection of it	mormation unless it contains a valid UMB control number	
Sub	ostitute for f	orm 1449A/PTC)		Complete if Known		
					Application Number	10/788,426	
IN	IFORM	NOITAN	DIS	CLOSURE	Filing Date	March 1, 2004	
S	TATE	MENT B'	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
					Art Unit	1625	
	(Us	se as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
04-				0.7	4 0. 1 . 11 . 1	DAVED 0044	

NON PATENT LITERATURE DOCUMENTS include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² Cite Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials * number(s), publisher, city and/or country where published Abandoned application Serial No. 10/308,187 filed December 3, 2002, Carrer et al., published as 2003-P385 0232765 12/18/2003 Abandoned application Serial No. 10/361.844 tiled February 11, 2003. Dumas et al., published as 2004-P386 0023961 2/5/2004 Abandoned application Serial No. 10/361.850 filed February 11, 2003, Dumas et al., published as US 2003-P387 0216396. 11/20/2003 Co-pending application Serial No. 10/361.859 filed February 11, 2003, Dumas et al., published as 2003-P388 0216446.11/20/2003 Co-Pending U.S. Patent Application No. 10/895,985 filed July 22, 2004, Boyer et al., published as US 2005-DSSO 0038080, 2/17/2005 Р389Ь Co-Pending U.S. Patent Application No. 11/932.548 filed October 31, 2007. Durnas et al., Co-Pending U.S. Patent Application No. 12/084,662 filed May 7, 2008, Sandner et al., published as 2010-P390 0035888, 2/11/2010 P391 Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al. P391a Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008. Wilhelm et al. P392 Co-Pending U.S. Patent Application No. 12/095,611 filed May 30, 2008, Smith et al. P393 Co-Pending U.S. Patent Application No. 12/158,524 filed June 20, 2008, Smith et al. P394 Co Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al. P394a Co Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009. Dumas et al., P395 Co Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009. Grunenberg et al. Examiner Date

EXAMINE: Table I reference considered, whether or not delates in a notiference, with IMEPT 800 Time line through addess in an accommendation of the control of the control

Considered

07/13/2011

/Heidi Reese/

Signature

This collection of information is required by 37 CFR1 (97 and 198. The information is required to obtain or return a browth by the public which is to life (and by the USFFIC) to a return of the public which is to life (and by the USFFIC) to a return of the public which is to life (and by the USFFIC) to a return of the public which is to life (and by the USFFIC) to a return of the public which is to the use of the u

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known 10/788 426 Application Number INFORMATION DISCLOSURE Filina Date March 1, 2004 STATEMENT BY APPLICANT First Named Inventor Jacques Dumas Art Unit 1625 (Use as many sheets as necessary) Examiner Name Heidi L. Reese Sheet 34 of 37 BAYER-0044

Attorney Docket Number

Conco.		57 PAROTES BOSICI NUMBER BY TELL TO 044
		NON PATENT LITERATURE DOCUMENTS
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), fitle of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	P396	Co Pending U.S. Patent Application No. 12/514,129 filed May 8, 2009, Grunenberg et al.
	P397	Co Pending U.S. Patent Application No. 12/514,715 filed May 13, 2009, Stiehl et al.
	P398	Co Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.
	P399	Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.
	P400	Co-pending U.S. Patent Application No. 12/523,652 field July 17, 2009, Wilhelm et al.
	P401	Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al.
	P402	Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009, Dumas et al.
	P402a	Co-Pending U.S. Patent Application No. 12/692,845 filed January 25, 2010, Dumas et al.
	P403	Co-Pending Application PCT/US09/61506, filed October 21. 2009, Carol Pena
	P404	International search report for International Application No. PCT/US98/10375 dated 9/3/58, Inhibition OI p38 Kinase Activity By Aryl Ureas, publication No. 98/52558, publication date 11/26/1998, 1 page
	P405	International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 96/52559, publication date 11/28/1998, 1 page
	P406	International search report for International Application No. PCT/US98/26078 dated 4/2/99, Inhibition Cf Rat Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32106, publication date 7/1/1999, 2 pages
	P407	International search report for International Application No. PCT/US98/28079 dated 4/12/99, inhibition OI p38 Kinase Activity Using Ayry And Hetercary/ Substituted Hetercaryclic Ureas, publication No. WO 99/32110, publication face 77/1999, 1 page
	P408	International search report for International Application No. PCT/USS6/28080 dated 4/12/99, Inhibition Of p35 kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page

"EXAMINE: Table I reference considered, whether or not clation in notiference, with IMEPS 600 thew line through validation if not in continuous and not considered included copy of the total continuous and notifered included copy of the total continuous and notifered included copy of the total copy of the continuous and notifered included inclu

/Heidi Reese/

Date

Considered

07/13/2011

Examiner

Signature

process) an application Confidentiality is governed by 35 U S C 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the use of the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of thine you reculied to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer. US Patentia and Trademation Officer, US Patentia and Trademation Officer, US Patentia and Trademation of Office, US Department of Commence, PO Son 1450, Alexandria, VA 2231314500 DN ONT SEND TEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Commissionner for Patents, P.O. Son 1450, Alexandria, VA 22313-1450.

Approved for use through 11/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	United alle Laberino	IN HOUUS	AUT AU UT 1880, TU POROUTO DE	s required to respond to a conscitor to it	Information diffess it contains a valid OND conto number	
Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	10/788,426	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 1, 2004	
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Jacques Dumas	
				Art Unit	1625	
	(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese	
5	O.F.	of	97	Atta David at Atta	DAVED 0044	

		NON PATENT LITERAT	URE DOCUMENTS			
Examiner Initials *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), tit the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-inol.					
	P409	International search report for International Applica RAF KINASE USING SYMMETRICAL AND UNSY publication No. WO 99/32436, publication date 7/1	MMETRICAL SUBS			
	P410	International search report for International Applics Kinase Using Aryl And Heteroaryl Substituted Hete date 7/1/1999, 1 page				
	P411	International search report for International Applica kinase using symmetrical and unsymmetrical diphe 7/1/99, 1 page				
	P412	International search report for International Applica Carboxyaryl Substituted Diphenyl Ureas as RAF K publication date 7/20/2000, 2 pages				
	P413	International search report for International Applica Aryl Substituted Diphenyl Ureas As p38 Kinase Int 7/20/2000, 1 page				
	P414	international search report for International Applica UREAS CONTAINING NITROGEN HETERO-ATC 02/085859, publication date 10/31/2002 2 pages				
	P415	International search report for International Applica Kinase Quinolyl, isoquinolyl Or Pyridyl Uress, publ	tion No. PCT/US02/ ication No. 02/08585	12066 dated 9/27/02, Inhibition Of Raf 7, publication date 10/31/2002, 2 pages		
	P416	Supplemental search report from the EPO for Euro Raf Kinase Using Symmetrical And Unsymmetrical publication date 7/1/1999, granted 3/16/2005, 4 pa	Substituted Diphens			
	P417	Supplemental search report from the EPO for Euro Or Raf Kinase Using Aryl And Heteroaryl Substitut date 7/1/1999, granted 6/7/2006, 4 pages	pean application EP ed Heterocyclic Urea	98963810.1 dated 12/21/00, Inhibition s. publication No. 1056725, publication		
	P418	Supplemental search report from the EPO for Euro Of Raf Kinase Using Substituted Heterocyclic Urea granted 7/27/2005 8 pages				
	P419	Supplemental search report from the EPO for Euro Carboxyaryl Substituted Diphenyl Ureas As Raf Ki 7/20/2000, granted 3/22/2006, 6 pages	pean application EP nase Inhibitors, publi	00903239.2 dated 8/7/02, Omega- cation no EP 1140840, published		
	P420	Supplemental search report from the EPO for Euro Carboxyaryl Substituted Diphenyl Ureas As p38 Ki pages				
	P431	English abstract of JP 10-306078, 1998-11-17, Pa	tent Abstracts of Jap	an, 2 pages		
	P432	English abstract of JP 08-301841, 1996-11-19, Par	tent Abstracts of Jap	an, 2 pages		
Examiner Signature		/Heidi Reese/	Date Considered	07/13/2011		

EVAINTER that If reference considered, whether or not calcition is in conformance with MEPF 000. Draw line through distalon if not in conformance and not considered an extraction of the conformation of the Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

P439

Paan

P441

P442

P443

P444

P445

P446

PTO/SB/08a (11-07)

Approved for use through 11/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademark Office; U.S. DEPA

Complete if Known

			Application Number	10/788,426	
INFO	RMA	TION DISCLOSURE	Filing Date	March 1, 2004	
STAT	TEME	NT BY APPLICANT	First Named Inventor	Jacques Dumas	
			Art Unit	1625	
	(Use as	many sheets as necessary)	Examiner Name	Heidi L. Reese	
Sheet	36	of 37	Attorney Docket Number	BAYER-0044	
		NON PATENT	LITERATURE DOCUMENTS		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.					T 2
	P433	English abstract of JP 03-198049, 1991-	08-29, Patent Abstracts of Japan.	1 page	
	P434	English abstract of JP 03-144634, 1991-	06-20, Patent Abstracts of Japan,	1 page	
	P435	English abstract of JP 03-053247, 1991-	03-07, Patent Abstracts of Japan,	1 page	
	P436	English abstract of JP 02-150840, 1990-	06-11, Patent Abstracts of Japan,	1 page	
	P437	English abstract of JP 02-108048, 1990-	04-19, Patent Abstracts of Japan.	1 page	
	P438	English abstract of JP 02-105146, 1990-	04-17, Patent Abstracts of Japan	1 page	

English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page

English abstract of JP 01-200254, 1989-08-11. Patent Abstracts of Japan, 1 page

English abstract of JP 01-259360, 1989-10-17. Patent Abstracts of Japan, 2 pages

English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page

English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page

English abstract of JP 05-180862, 1993-07-23, Patent Abstracts of Japan, 1 page

English abstract of JP 05-163170, 1993-06-29, Patent Abstracts of Japan, 1 page

English abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page

Examiner
Signature

FEANINER: Inhal I reference considered, whether or not obtain is in conformance with MFEP 609 Draw line through obtain if in a nontomance and not considered include copy of the form with near communication to applicant. Applicant's unapper obtains designation number (optional). See Rinds Godes of USFO Patent Documents as well as the property of the form with near communication to applicant. Applicant's unapper obtains designation number (optional). See Rinds Godes of USFO Patent Documents as well as the property of the form with near the content of the formation of the designation number (optional). See Rinds Godes of USFO Patent Documents of 3). For appearance and obtained on the designation number (optional) are included on the decimation of the designation of the decimation of the decimat

This collection of information is required by 37 CFR 1 97 and 1 98. The information is required to obtain or return a brownful by the public which is to like (gast by the USFFI to 1 98.) and the public which is to like (gast by the USFFI to 1 98.) and the unity of the USFFI to 1 98. The USFFI to 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /H.B./

PTO/SB/08a (11-07)

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		Under the Laberton	IK I IBUU	JOHN ACTIONS, NO PERSONS OF	required to respond to a conscitor of militarian diress it contains a valid Civib control national			
	Substitute	for form 1449A/PTC)		Complete if Known			
					Application Number	10/788,426		
				CLOSURE	Filing Date	March 1, 2004		
	STAT	EMENT B	ΥΑ	PPLICANT	First Named Inventor	Jacques Dumas		
					Art Unit	1625		
		(Use as many she	ets as	necessary)	Examiner Name	Heidi L. Reese		
Ū	Sheet	37	of	37	Attorney Docket Number	BAYER-0044		

(Use as many sheets as necessary)			necessary)	Examiner Name		Heidi	Heidi L. Reese				
Sheet	37	of	37	Attorr	ey Docket Number	BAYE	R-0044				
			NON PATENT	LITERAT	URE DOCUMENTS						
Examiner Initials *	Cite No.1		ok, magazine, journal, s	PITAL LETTERS), title of the article (when appropriate), title of serial, symposium, catalog, etc.), date, page(s), volume-issue blisher, city and/or country where published.				T ²			
	P447	English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages									
	P448	English abstract of JP 50-149668 A and JP 56-29671 B, Derwent World Patents Index, Dialog File No. 351. Acc No. 1498399, 3 pages 1974									
	P449	English abstract of JP S3-086033, 1978-07-29, Patent Abstracts of Japan, 1 page									
	P450	English abstra	ent Abstracts of Jap	an, 1 page							
	P451	English abstra	ct of JP 55-098152, 1980-0	7-25, Pa	ent Abstracts of Jap	an, 1 page					
	P452	English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page									
	P453	English abstract of JP 02-023337, 1979-03-09, Patent Abstracts of Japan, 2 pages									
	P454	English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages									
	P455	English abstract of DD 253997 A, 1988-02-10, 1 page									
	P456	English abstra	glish abstract of DES11468, European Patent Office, 2 pages; 10/30/1930								
	P457	Co-Pending U	Pending U.S. Patent Application No. 12/619,913, filed November 17, 2009, Ranges et al.								
	T-P3a	Arzneimittelfherapie, "Sorafenib" Cotober 6, 2006, Auflage 18498, 7 pages English transistion									
Examiner Signature		/Heid	/Heidi Reese/		Date Considered		07/13/2011				

"EXAMPER Initial if reference considered, whether or not obtation is in conformance with MIPEP 609 Draw line through obtation if not in conformance and not considered include copy of this form with next communication to applicant." Applicant's unique obtation designation number (optional). See Rinds Codes of USPTO Patient Documents a way sugging our NoTPP 90.10 or Effect from the last based the document, by the two-feets code (NIPC) Standard ST 3). For Lapeanese plent documents, in the reduction of the year of he regno of the Emperor must precede the cereal number of the patient document. If when the community is not the patient document by the appropriate symbols as indicated on the document under WPO Standard ST in For postable "Applicant is to place a check make here it English insupaga Transistions in supplementations and in the standard of the patient document in the standard of the patient document."

WPO Standard ST 16 (possible "Applicant is to place a check mark here if English Ingragage Transition is attituded." This Colection of Indiramsian as required by 20°TG 187 at and 18 Pm. Indirection or required by 20°TG 187 at and 18 Pm. Indirections or required by 20°TG 187 at and 18 Pm. Indirections or required by 20°TG 187 at and 18 Pm. Indirections or required by 20°TG 187 at a 20°TG 11 14. This collection is estimated to take 2 hours to complete, including gathering, preparing and calming the completed application from the USPTO To make will very depending upon the indirection care. We comment to the sound of time you consider the completed application from the USPTO To make will very depending upon the indirection care. We comment to the sound of time you consider the complete of the complete application from the USPTO To make will very depending upon the indirection care. We comment to the sound of the will be completed application from the USPTO To make a 20°TG 18 Pm. Indirection 20°TG 18 Pm. Indire

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /H.R./